# Molecular therapies and precision medicine for hepatoc

Nature Reviews Clinical Oncology

15, 599-616

DOI: 10.1038/s41571-018-0073-4

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability. Translational Gastroenterology and Hepatology, 2018, 3, 84-84. | 1.5 | 14 |
| 2 | Prognostic Value of Lactate Dehydrogenase in Patients with Hepatocellular Carcinoma: A Meta-Analysis. BioMed Research International, 2018, 2018, 1-10. | 0.9 | 17 |
| 3 | Lipid Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers, 2018, 10, 447. | 1.7 | 107 |
| 4 | Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Communications, 2018, 9, 4962. | 5.8 | 111 |
| 5 | Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer. Frontiers in Oncology, 2018, 8, 459. | 1.3 | 71 |
| 6 | Current State of Immunotherapy for HCCâ€"Supporting Data and Toxicity Management. Current Hepatology Reports, 2018, 17, 434-443. | 0.4 | 2 |
| 7 | Hypoxia-Inducible Factor Prolyl 4-Hydroxylases and Metabolism. Trends in Molecular Medicine, 2018, 24, 1021-1035. | 3.5 | 34 |
| 8 | HBx regulates transcription factor PAX8 stabilization to promote the progression of hepatocellular carcinoma. Oncogene, 2019, 38, 6696-6710. | 2.6 | 17 |
| 9 | miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway. Cancer Cell International, 2019, 19, 205. | 1.8 | 28 |
| 10 | Inhibition of GSK-3Î² activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling. Cancer Letters, 2019, 463, 11-26. | 3.2 | 53 |
| 11 | Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. BMC Cancer, 2019, 19, 789. | 1.1 | 12 |
| 12 | Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. Npj Systems Biology and Applications, 2019, 5, 29. | 1.4 | 17 |
| 13 | Biology and significance of alphaâ€fetoprotein in hepatocellular carcinoma. Liver International, 2019, 39, 2214-2229. | 1.9 | 327 |
| 14 | New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers, 2019, 11, 1086. | 1.7 | 41 |
| 15 | Mechanisms of hepatocellular carcinoma progression. World Journal of Gastroenterology, 2019, 25, 2279-2293. | 1.4 | 157 |
| 16 | Proteomic profiling in liver cancer: another new page. Translational Gastroenterology and Hepatology, 2019, 4, 47-47. | 1.5 | 8 |
| 17 | Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. Cancers, 2019, 11, 930. | 1.7 | 8 |
| 18 | Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. British Journal of Cancer, 2019, 121, 340-343. | 2.9 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis. Targeted Oncology, 2019, 14, 395-403. | 1.7 | 10 |
| 20 | Immunomodulatory TGF-Î² Signaling in Hepatocellular Carcinoma. Trends in Molecular Medicine, 2019, 25, 1010-1023. | 3.5 | 157 |
| 21 | Remote targeted implantation of sound-sensitive biodegradable multi-cavity microparticles with focused ultrasound. Scientific Reports, 2019, 9, 9612. | 1.6 | 18 |
| 22 | Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology, 2019, 157, 760-776. | 0.6 | 141 |
| 23 | Identifying potential drug targets in hepatocellular carcinoma based on network analysis and one-class support vector machine. Scientific Reports, 2019, 9, 10442. | 1.6 | 17 |
| 24 | <p>MicroRNA-106b-5p promotes hepatocellular carcinoma development via modulating FOG2</p>. OncoTargets and Therapy, 2019, Volume 12, 5639-5647. | 1.0 | 13 |
| 25 | Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein. Nano Letters, 2019, 19, 5266-5276. | 4.5 | 40 |
| 26 | Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment. European Journal of Pharmaceutical Sciences, 2019, 137, 104978. | 1.9 | 33 |
| 28 | PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer. Journal of Translational Medicine, 2019, 17, 343. | 1.8 | 42 |
| 29 | Cabozantinib for the treatment of hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 847-855. | 1.1 | 12 |
| 30 | Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells. Cancer Immunology Research, 2019, 7, 1813-1823. | 1.6 | 85 |
| 31 | An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Gastroenterology, 2019, 157, 1383-1397.e11. | 0.6 | 62 |
| 33 | <p>Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine</p>. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 151-166. | 1.8 | 25 |
| 34 | Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers, 2019, 11, 1689. | 1.7 | 44 |
| 35 | Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 447. | 3.5 | 149 |
| 36 | Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers. Life Sciences, 2019, 239, 117013. | 2.0 | 45 |
| 37 | Simple In-House Fabrication of Microwells for Generating Uniform Hepatic Multicellular Cancer Aggregates and Discovering Novel Therapeutics. Materials, 2019, 12, 3308. | 1.3 | 8 |
| 38 | A cis â€eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma. Cancer Medicine, 2019, 8, 6476-6484. | 1.3 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 39 | Râ€śspondin 2 Drives Liver Tumor Development in a Yesâ€Associated Proteinâ€Dependent Manner. Hepatology Communications, 2019, 3, 1496-1509. | 2.0 | 15 |
| 40 | Targeted Drug-Loaded Chemical Probe Staining Assay to Predict Therapy Response and Function as an Independent Pathological Marker. IScience, 2019, 21, 549-561. | 1.9 | 1 |
| 41 | Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2. International Immunopharmacology, 2019, 76, 105855. | 1.7 | 10 |
| 42 | Macrophage-associated lncRNA ELMO1-AS1: a novel therapeutic target and prognostic biomarker for hepatocellular carcinoma . OncoTargets and Therapy, 2019, Volume 12, 6203-6216. | 1.0 | 13 |
| 43 | Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 62-65. | 1.0 | 21 |
| 44 | New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 56-61. | 1.0 | 23 |
| 45 | Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress. Cancers, 2019, 11, 1453. | 1.7 | 15 |
| 46 | GRIM-19 over-expression represses the proliferation and invasion of orthotopically implanted hepatocarcinoma tumors associated with downregulation of Stat3 signaling. BioScience Trends, 2019, 13, 342-350. | 1.1 | 9 |
| 47 | Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Experimental and Molecular Medicine, 2019, 51, 1-15. | 3.2 | 52 |
| 48 | Adoptive cell transfer therapy for hepatocellular carcinoma. Frontiers of Medicine, 2019, 13, 3-11. | 1.5 | 45 |
| 49 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased Î±-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 282-296. | 5.1 | 1,202 |
| 50 | Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis. International Journal of Molecular Sciences, 2019, 20, 2507. | 1.8 | 45 |
| 51 | Liver resection versus chemoembolization for patients with multifocal hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 543-545. | 0.7 | 0 |
| 52 | Gammaâ€secretase complexâ€dependent intramembrane proteolysis of CD147 regulates the Notch1 signaling pathway in hepatocellular carcinoma. Journal of Pathology, 2019, 249, 255-267. | 2.1 | 22 |
| 53 | Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. Cells, 2019, 8, 618. | 1.8 | 14 |
| 54 | Molecular and histological correlations in liver cancer. Journal of Hepatology, 2019, 71, 616-630. | 1.8 | 308 |
| 55 | Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4Î±. Theranostics, 2019, 9, 2606-2617. | 4.6 | 40 |
| 56 | A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research, 2019, 25, 5202-5211. | 3.2 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 57 | Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. Endocrine Journal, 2019, 66, 787-792. | 0.7 | 20 |
| 58 | Î²-ionone inhibits nonalcoholic fatty liver disease and its association with hepatocarcinogenesis in male Wistar rats. Chemico-Biological Interactions, 2019, 308, 377-384. | 1.7 | 5 |
| 59 | Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€“PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141. | 7.7 | 498 |
| 60 | Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility. Cancers, 2019, 11, 787. | 1.7 | 8 |
| 61 | Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma. Medicine (United States), 2019, 98, e14823. | 0.4 | 4 |
| 62 | Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 248-260. | 1.8 | 8 |
| 63 | Liver Zonation in Health and Disease: Hypoxia and Hypoxia-Inducible Transcription Factors as Concert Masters. International Journal of Molecular Sciences, 2019, 20, 2347. | 1.8 | 56 |
| 64 | Hepatocellular carcinoma: killing one bird with two stones. Gut, 2019, 68, 1543-1544. | 6.1 | 3 |
| 65 | Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clinical Pharmacokinetics, 2019, 58, 983-1014. | 1.6 | 17 |
| 66 | MALAT1 functions as a competing endogenous RNA to regulate SMAD5 expression by acting as a sponge for miR-142-3p in hepatocellular carcinoma. Cell and Bioscience, 2019, 9, 39. | 2.1 | 23 |
| 67 | Random gene sets in predicting survival of patients with hepatocellular carcinoma. Journal of Molecular Medicine, 2019, 97, 879-888. | 1.7 | 15 |
| 69 | <p>A novel theranostic gold nanorods- and Adriamycin-loaded micelle for EpCAM targeting, laser ablation, and photoacoustic imaging of cancer stem cells in hepatocellular carcinoma</p>. International Journal of Nanomedicine, 2019, Volume 14, 1877-1892. | 3.3 | 36 |
| 70 | Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma. European Journal of Histochemistry, 2019, 63, . | 0.6 | 6 |
| 71 | KrÃ¼ppelâ€like factor 2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway. Cancer Science, 2019, 110, 1220-1231. | 1.7 | 23 |
| 72 | Epithelialâ€“mesenchymal transition induced cancerâ€stemâ€cellâ€like characteristics in hepatocellular carcinoma. Journal of Cellular Physiology, 2019, 234, 18448-18458. | 2.0 | 18 |
| 73 | Expression of IL-26 predicts prognosis of patients with hepatocellular carcinoma after surgical resection. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 242-248. | 0.6 | 8 |
| 74 | <p>CD24 isoform a promotes cell proliferation, migration and invasion and is downregulated by EGR1 in hepatocellular carcinoma</p>. OncoTargets and Therapy, 2019, Volume 12, 1705-1716. | 1.0 | 23 |
| 75 | Network Pharmacology and Bioinformatics Approach Reveals the Therapeutic Mechanism of Action of Baicalein in Hepatocellular Carcinoma. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-15. | 0.5 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 76 | Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. Pharmacological Research, 2019, 143, 73-85. | 3.1 | 29 |
| 77 | KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program. Cancer Letters, 2019, 454, 78-89. | 3.2 | 41 |
| 78 | Hunting hidden pieces of signaling pathways in hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 74-76. | 0.7 | 0 |
| 79 | Hepatocellular Carcinoma. New England Journal of Medicine, 2019, 380, 1450-1462. | 13.9 | 2,966 |
| 80 | CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110Î² and predicts poor prognosis. Journal of Hematology and Oncology, 2019, 12, 37. | 6.9 | 150 |
| 81 | Developing small activating RNA as a therapeutic: current challenges and promises. Therapeutic Delivery, 2019, 10, 151-164. | 1.2 | 49 |
| 82 | Identification of molecular transition of hepatocellular carcinoma: a novel method to predict the initiation of metastasis. Stem Cell Investigation, 2019, 6, 5-5. | 1.3 | 2 |
| 83 | The Potential Implication of the Autonomic Nervous System in Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 145-148. | 2.3 | 4 |
| 84 | Dynamic edge-based biomarker non-invasively predicts hepatocellular carcinoma with hepatitis B virus infection for individual patients based on blood testing. Journal of Molecular Cell Biology, 2019, 11, 665-677. | 1.5 | 17 |
| 85 | Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology, 2019, 70, 1262-1277. | 1.8 | 150 |
| 86 | Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. Frontiers of Medicine, 2019, 13, 12-23. | 1.5 | 14 |
| 87 | Aberrant Superâ€Enhancer Landscape in Human Hepatocellular Carcinoma. Hepatology, 2019, 69, 2502-2517. | 3.6 | 90 |
| 88 | Hepatocellular carcinoma: H-Prune gene regulatory networks. EBioMedicine, 2019, 41, 21-22. | 2.7 | 2 |
| 89 | Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visceral Medicine, 2019, 35, 43-46. | 0.5 | 6 |
| 90 | High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma. Disease Markers, 2019, 2019, 1-11. | 0.6 | 25 |
| 92 | Systemic management for patients with hepatobiliary tumors in a multi-dimensional view. Hepatobiliary Surgery and Nutrition, 2019, 8, 626-628. | 0.7 | 6 |
| 93 | Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 2055-2066. | 2.0 | 94 |
| 94 | Systemic Therapy for Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 695-715. | 0.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 95 | YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Molecular Cancer, 2019, 18, 163. | 7.9 | 230 |
| 96 | Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. , 2019, 7, 333. | | 129 |
| 97 | First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1696-1707. | 7.7 | 157 |
| 98 | Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance. Medicine (United States), 2019, 98, e15755. | 0.4 | 6 |
| 99 | Second-line Treatments of Advanced Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2019, 53, 251-261. | 1.1 | 19 |
| 100 | <p>Unleashing The Potential Of Multiple-Targeted Therapies In Hepatobiliary Cancers: Two Cases, Cocktail Therapy With Nine Molecular Targeted Agents And Long-Lasting Survival</p>. OncoTargets and Therapy, 2019, Volume 12, 9941-9945. | 1.0 | 0 |
| 101 | HIF-1-miR-219-SMC4 Regulatory Pathway Promoting Proliferation and Migration of HCC under Hypoxic Condition. BioMed Research International, 2019, 2019, 1-9. | 0.9 | 19 |
| 102 | Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells. Anti-Cancer Drugs, 2019, 30, 209-217. | 0.7 | 16 |
| 103 | Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology, 2019, 156, 510-524. | 0.6 | 179 |
| 104 | Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC. Clinical Cancer Research, 2019, 25, 2021-2023. | 3.2 | 152 |
| 105 | Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. Future Oncology, 2019, 15, 563-565. | 1.1 | 2 |
| 106 | The synergistic effect of sorafenib and TNF-Î± inhibitor on hepatocellular carcinoma. EBioMedicine, 2019, 40, 11-12. | 2.7 | 5 |
| 107 | PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway. Life Sciences, 2019, 219, 182-189. | 2.0 | 22 |
| 108 | Medical oncologists must get more involved in systemic treatment. Annals of Oncology, 2019, 30, 6-8. | 0.6 | 2 |
| 109 | Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery. Molecular Imaging and Biology, 2020, 22, 476-485. | 1.3 | 35 |
| 110 | Construction of a Plasmonic Chip for Metabolic Analysis in Cervical Cancer Screening and Evaluation. Small Methods, 2020, 4, 1900469. | 4.6 | 55 |
| 111 | Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression. Gut, 2020, 69, 329-342. | 6.1 | 39 |
| 112 | FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances Doxorubicin-induced cytotoxicity. Experimental Cell Research, 2020, 387, 111714. | 1.2 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 113 | The promise of adoptive cellular immunotherapies in hepatocellular carcinoma. OncoImmunology, 2020, 9, 1673129. | 2.1 | 26 |
| 114 | Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression. Cancer Research, 2020, 80, 561-575. | 0.4 | 27 |
| 115 | Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. Journal of Hematology and Oncology, 2020, 13, 3. | 6.9 | 163 |
| 116 | UBQLN4 promotes progression of HCC via activating wnt-Î²-catenin pathway and is regulated by miR-370. Cancer Cell International, 2020, 20, 3. | 1.8 | 21 |
| 117 | Collaborative assembly of doxorubicin and galactosyl diblock glycopolymers for targeted drug delivery of hepatocellular carcinoma. Biomaterials Science, 2020, 8, 189-200. | 2.6 | 20 |
| 118 | Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis, 2020, 23, 55-74. | 3.7 | 77 |
| 119 | Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. Frontiers of Medicine, 2020, 14, 273-283. | 1.5 | 9 |
| 120 | Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with Î±-fetoprotein concentrations of at least 400â€‰ng/ml. Journal of Medical Economics, 2020, 23, 347-352. | 1.0 | 12 |
| 121 | Immune Therapy for Liver Cancers. Cancers, 2020, 12, 77. | 1.7 | 49 |
| 122 | Favorable radiological antitumor response at 2Âweeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatology Research, 2020, 50, 374-381. | 1.8 | 25 |
| 123 | Harnessing big â€˜omicsâ€™ data and AI for drug discovery in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 238-251. | 8.2 | 90 |
| 124 | Tumor necrosis factor Î±-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-ÎºB activation in hepatocellular carcinoma. EBioMedicine, 2020, 51, 102603. | 2.7 | 25 |
| 125 | IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-ÎºB signaling pathway. Digestive and Liver Disease, 2020, 52, 573-581. | 0.4 | 20 |
| 126 | Correlation of molecular and morphologic effects of thermoembolization in a swine model using mass spectrometry imaging. Journal of Mass Spectrometry, 2020, 55, e4477. | 0.7 | 1 |
| 127 | Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatology International, 2020, 14, 80-95. | 1.9 | 15 |
| 128 | Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma. Biomacromolecules, 2020, 21, 716-724. | 2.6 | 20 |
| 129 | Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future. Genes and Diseases, 2020, 7, 370-379. | 1.5 | 76 |
| 130 | Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells. Cancer Biology and Therapy, 2020, 21, 269-277. | 1.5 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 131 | Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles. Biomedicine and Pharmacotherapy, 2020, 121, 109637. | 2.5 | 46 |
| 132 | Functional Genomics Identifies Hepatitis-Induced STAT3â€“TYRO3â€“STAT3 Signaling as a Potential Therapeutic Target of Hepatoma. Clinical Cancer Research, 2020, 26, 1185-1197. | 3.2 | 12 |
| 133 | MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. Cancer Genomics and Proteomics, 2020, 17, 1-21. | 1.0 | 23 |
| 134 | Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2020, 123, 109780. | 2.5 | 42 |
| 135 | The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2020, 132, 110797. | 2.5 | 35 |
| 136 | Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 591-610. | 1.0 | 19 |
| 137 | Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells. ACS Omega, 2020, 5, 24838-24847. | 1.6 | 16 |
| 138 | Icaritinâ€induced immunomodulatory efficacy in advanced hepatitis B virusâ€related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. Cancer Science, 2020, 111, 4218-4231. | 1.7 | 40 |
| 139 | Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers, 2020, 12, 2729. | 1.7 | 12 |
| 140 | Targeting Ca2+ Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma. Cancers, 2020, 12, 2755. | 1.7 | 11 |
| 141 | A comprehensive analysis of the MAGE family as prognostic and diagnostic markers for hepatocellular carcinoma. Genomics, 2020, 112, 5101-5114. | 1.3 | 17 |
| 142 | Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 788-791. | 0.6 | 1 |
| 143 | Cell-penetrating peptides in oncologic pharmacotherapy: A review. Pharmacological Research, 2020, 162, 105231. | 3.1 | 32 |
| 144 | <p>Dual-Effect of Magnetic Resonance Imaging Reporter Gene in Diagnosis and Treatment of Hepatocellular Carcinoma</p>. International Journal of Nanomedicine, 2020, Volume 15, 7235-7249. | 3.3 | 9 |
| 145 | Bismuthâ€Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma. Advanced Healthcare Materials, 2020, 9, e2000650. | 3.9 | 14 |
| 146 | Immunotherapy for advanced hepatocellular carcinoma, where are we?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188441. | 3.3 | 52 |
| 148 | Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers, 2020, 12, 1867. | 1.7 | 56 |
| 149 | Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators. European Journal of Medicinal Chemistry, 2020, 204, 112608. | 2.6 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 150 | Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma. BMC Cancer, 2020, 20, 1136. | 1.1 | 16 |
| 151 | Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 589908. | 1.3 | 26 |
| 152 | Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma. Cell Death and Disease, 2020, 11, 1017. | 2.7 | 49 |
| 153 | An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. Cancers, 2020, 12, 3583. | 1.7 | 16 |
| 154 | Single-Cell Spatial Analysis of Tumor and Immune Microenvironment on Whole-Slide Image Reveals Hepatocellular Carcinoma Subtypes. Cancers, 2020, 12, 3562. | 1.7 | 21 |
| 155 | Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis. Cancer Control, 2020, 27, 107327482097711. | 0.7 | 14 |
| 156 | NF-Y Overexpression in Liver Hepatocellular Carcinoma (HCC). International Journal of Molecular Sciences, 2020, 21, 9157. | 1.8 | 20 |
| 157 | Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient . OncoTargets and Therapy, 2020, Volume 13, 12477-12487. | 1.0 | 9 |
| 158 | The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 2020, 55, 1441-1446. | 0.6 | 7 |
| 159 | Animal Models: A Useful Tool to Unveil Metabolic Changes in Hepatocellular Carcinoma. Cancers, 2020, 12, 3318. | 1.7 | 3 |
| 160 | CK19-positive Hepatocellular Carcinoma is a Characteristic Subtype. Journal of Cancer, 2020, 11, 5069-5077. | 1.2 | 55 |
| 161 | A Five-Gene Signature Based on Stromal/Immune Scores in the Tumor Microenvironment and Its Clinical Implications for Liver Cancer. DNA and Cell Biology, 2020, 39, 1621-1638. | 0.9 | 36 |
| 162 | The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1017-1024. | 1.4 | 14 |
| 163 | 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery and Nutrition, 2020, 9, 452-463. | 0.7 | 267 |
| 164 | Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Pathways Associated With Clinical Outcome in Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 814. | 1.1 | 11 |
| 165 | SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling. Journal of Cellular and Molecular Medicine, 2020, 24, 10714-10729. | 1.6 | 28 |
| 166 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 2020, 38, 2960-2970. | 0.8 | 723 |
| 167 | Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Reports, 2020, 2, 100167. | 2.6 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 168 | Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. Cell Systems, 2020, 11, 196-207.e7. | 2.9 | 24 |
| 169 | Rictor promotes cell migration and actin polymerization through regulating ABLIM1 phosphorylation in Hepatocellular Carcinoma. International Journal of Biological Sciences, 2020, 16, 2835-2852. | 2.6 | 9 |
| 170 | The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death and Disease, 2020, 11, 902. | 2.7 | 62 |
| 171 | Differential Proteomic Analysis of Hepatocellular Carcinomas from Ppp2r5d Knockout Mice and Normal (Knockout) Livers. Cancer Genomics and Proteomics, 2020, 17, 669-685. | 1.0 | 5 |
| 172 | Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 541479. | 1.3 | 26 |
| 173 | Reactive Oxygen Species Induce Endothelial Differentiation of Liver Cancer Stem-Like Sphere Cells through the Activation of Akt/IKK Signaling Pathway. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-11. | 1.9 | 14 |
| 174 | Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 6350-6361. | 3.2 | 35 |
| 175 | Hepatocellular Carcinoma-associated microRNAs Induced by Hepatoma-derived Growth Factor Stimulation. In Vivo, 2020, 34, 2297-2301. | 0.6 | 2 |
| 176 | Long Non-Coding RNAs in Liver Cancer and Nonalcoholic Steatohepatitis. Non-coding RNA, 2020, 6, 34. | 1.3 | 11 |
| 177 | RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A. Scientific Reports, 2020, 10, 14538. | 1.6 | 15 |
| 178 | Evaluating Distribution and Prognostic Value of New Tumor-Infiltrating Lymphocytes in HCC Based on a scRNA-Seq Study With CIBERSORTx. Frontiers in Medicine, 2020, 7, 451. | 1.2 | 15 |
| 179 | Targeting signalling pathways and the immune microenvironment of cancer stem cells â€" a clinical update. Nature Reviews Clinical Oncology, 2020, 17, 204-232. | 12.5 | 431 |
| 180 | Functional nanostructure-loaded three-dimensional graphene foam as a non-enzymatic electrochemical sensor for reagentless glucose detection. RSC Advances, 2020, 10, 33739-33746. | 1.7 | 45 |
| 181 | The Importance of AFP in Liver Transplantation for HCC. Journal of Gastrointestinal Cancer, 2020, 51, 1127-1132. | 0.6 | 29 |
| 182 | Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterology, 2020, 20, 251. | 0.8 | 9 |
| 183 | Gd-EOB-DTPA-MRI Could Predict WNT/Î²-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 479-490. | 4.2 | 42 |
| 184 | Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 2495. | 1.7 | 12 |
| 185 | Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy. Technology in Cancer Research and Treatment, 2020, 19, 153303382094427. | 0.8 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 186 | Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy. Theranostics, 2020, 10, 10245-10261. | 4.6 | 31 |
| 187 | Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. Liver Cancer, 2020, 9, 613-624. | 4.2 | 45 |
| 188 | Development of a novel melatonin-modified near-infrared fluorescent probe for in vivo hepatocellular carcinoma imaging. Analytical Methods, 2020, 12, 4556-4561. | 1.3 | 3 |
| 189 | Bromoâ€•and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma. Cancer Science, 2020, 111, 3503-3515. | 1.7 | 17 |
| 190 | Butyrate-containing structured lipids inhibit RAC1 and epithelial-to-mesenchymal transition markers: a chemopreventive mechanism against hepatocarcinogenesis. Journal of Nutritional Biochemistry, 2020, 86, 108496. | 1.9 | 8 |
| 191 | Deciphering Antitumor Mechanism of Pien Tze Huang in Mice of Hepatocellular Carcinoma Based on Proteomics. Journal of Immunology Research, 2020, 2020, 1-14. | 0.9 | 9 |
| 192 | Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. Hepatology, 2021, 74, 233-247. | 3.6 | 18 |
| 193 | The dichotomous role of TGF-Î² in controlling liver cancer cell survival and proliferation. Journal of Genetics and Genomics, 2020, 47, 497-512. | 1.7 | 21 |
| 194 | Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma. Anticancer Research, 2020, 40, 3953-3960. | 0.5 | 5 |
| 195 | Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology, 2020, 11, 598877. | 2.2 | 133 |
| 196 | Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut, 2021, 70, 1746-1757. | 6.1 | 60 |
| 197 | Functional and Clinical Characterization of Tumor-Infiltrating T Cell Subpopulations in Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 586415. | 1.1 | 7 |
| 199 | New systemic agents for hepatocellular carcinoma: an update 2020. Current Opinion in Gastroenterology, 2020, 36, 177-183. | 1.0 | 17 |
| 200 | New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates, 2020, 51, 100702. | 6.5 | 53 |
| 201 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer, 2020, 9, 245-260. | 4.2 | 172 |
| 202 | <p>MicroRNA-375 Targets ATG14 to Inhibit Autophagy and Sensitize Hepatocellular Carcinoma Cells to Sorafenib</p>. OncoTargets and Therapy, 2020, Volume 13, 3557-3570. | 1.0 | 23 |
| 203 | Predictive value of hypoxia, metabolism and immune factors for prognosis in hepatocellular carcinoma: a retrospective analysis and multicenter validation study. Journal of Cancer, 2020, 11, 4145-4156. | 1.2 | 4 |
| 204 | Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clinical Cancer Research, 2020, 26, 3979-3989. | 3.2 | 184 |

| # | Article | IF | Citations |
|---|---|---|---|
| 205 | Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer, 2020, 20, 483. | 1.1 | 5 |
| 206 | Molecular Profiling in Drug Development: Paving a Way Forward. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e309-e318. | 1.8 | 5 |
| 207 | The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma. Molecular Therapy - Nucleic Acids, 2020, 21, 13-27. | 2.3 | 29 |
| 208 | Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics, 2020, 10, 338. | 1.3 | 14 |
| 209 | Interaction of FGF9 with FGFR3â€IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma. Liver International, 2020, 40, 2279-2290. | 1.9 | 13 |
| 210 | FOXC2 is a prognostic biomarker and contributes to the growth and invasion of human hepatocellular carcinoma. Cancer Cell International, 2020, 20, 196. | 1.8 | 9 |
| 211 | Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis. International Journal of Hyperthermia, 2020, 37, 624-633. | 1.1 | 13 |
| 212 | PRMT2 accelerates tumorigenesis of hepatocellular carcinoma by activating Bcl2 via histone H3R8 methylation. Experimental Cell Research, 2020, 394, 112152. | 1.2 | 31 |
| 213 | Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma. Cancers, 2020, 12, 1419. | 1.7 | 91 |
| 214 | Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells, 2020, 9, 1370. | 1.8 | 256 |
| 215 | Computational Analysis of Transcriptomic and Proteomic Data for Deciphering Molecular Heterogeneity and Drug Responsiveness in Model Human Hepatocellular Carcinoma Cell Lines. Genes, 2020, 11, 623. | 1.0 | 3 |
| 216 | <p>Diosmetin Inhibits Cell Proliferation, Induces Cell Apoptosis and Cell Cycle Arrest in Liver Cancer</p>. Cancer Management and Research, 2020, Volume 12, 3537-3546. | 0.9 | 24 |
| 217 | New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188382. | 3.3 | 54 |
| 218 | Solasonine promotes ferroptosis of hepatoma carcinoma cells via glutathione peroxidase 4-induced destruction of the glutathione redox system. Biomedicine and Pharmacotherapy, 2020, 129, 110282. | 2.5 | 77 |
| 219 | <p>OTUD4: A Potential Prognosis Biomarker for Multiple Human Cancers</p>. Cancer Management and Research, 2020, Volume 12, 1503-1512. | 0.9 | 14 |
| 220 | <p>Gluconokinase IDNK Promotes Cell Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma</p>. OncoTargets and Therapy, 2020, Volume 13, 1767-1776. | 1.0 | 2 |
| 221 | The Cancer Stem Cell in Hepatocellular Carcinoma. Cancers, 2020, 12, 684. | 1.7 | 34 |
| 222 | JAK/STAT signaling in hepatocellular carcinoma. Hepatic Oncology, 2020, 7, HEP18. | 4.2 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 223 | Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes and Diseases, 2020, 7, 320-327. | 1.5 | 10 |
| 224 | USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ. Cancer Research, 2020, 80, 2204-2216. | 0.4 | 101 |
| 225 | Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 1197-1209. | 1.9 | 49 |
| 226 | Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 269-285. | 2.3 | 14 |
| 227 | Hypoxia-Induced lncRNA-NEAT1 Sustains the Growth of Hepatocellular Carcinoma via Regulation of miR-199a-3p/UCK2. Frontiers in Oncology, 2020, 10, 998. | 1.3 | 33 |
| 228 | The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development, 2020, 5, 253-263. | 0.4 | 0 |
| 229 | Construction of a Comprehensive Multiomics Map of Hepatocellular Carcinoma and Screening of Possible Driver Genes. Frontiers in Genetics, 2020, 11, 634. | 1.1 | 6 |
| 230 | Recent advances in nanomaterial-enhanced biosensing methods for hepatocellular carcinoma diagnosis. TrAC - Trends in Analytical Chemistry, 2020, 130, 115965. | 5.8 | 17 |
| 231 | Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093248. | 1.4 | 10 |
| 232 | Circulating Tumor Cell Migration Requires Fibronectin Acting through Integrin B1 or SLUG. Cells, 2020, 9, 1594. | 1.8 | 9 |
| 233 | Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers, 2020, 12, 1668. | 1.7 | 54 |
| 234 | Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs, 2020, 80, 315-322. | 4.9 | 38 |
| 235 | Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met. Toxicology and Applied Pharmacology, 2020, 392, 114918. | 1.3 | 14 |
| 236 | Phenotypic Response and Personalized Medicine in Liver Cancer and Transplantation: Approaches to Complex Systems. Advanced Therapeutics, 2020, 3, 1900167. | 1.6 | 2 |
| 237 | Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. Lancet Oncology, The, 2020, 21, 479-481. | 5.1 | 29 |
| 238 | A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6103-6113. | 3.3 | 39 |
| 239 | Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transplantation, 2020, 26, 823-831. | 1.3 | 25 |
| 240 | Adoptive T-cell therapy for HBV-associated HCC and HBV infection. Antiviral Research, 2020, 176, 104748. | 1.9 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 241 | Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma. Cancer Letters, 2020, 476, 120-128. | 3.2 | 17 |
| 242 | Hepatocellular carcinomaâ€"united forces against a global killer. Annals of Oncology, 2020, 31, 449-450. | 0.6 | 6 |
| 243 | Mass Spectrometric Assay of Alpha-Fetoprotein Isoforms for Accurate Serological Evaluation. Analytical Chemistry, 2020, 92, 4807-4813. | 3.2 | 29 |
| 244 | Advances in resection and transplantation for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 262-276. | 1.8 | 107 |
| 245 | Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules, 2020, 10, 117. | 1.8 | 39 |
| 246 | Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer. Cancers, 2020, 12, 147. | 1.7 | 24 |
| 247 | 1H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages. Cancers, 2020, 12, 241. | 1.7 | 39 |
| 248 | mRECIST for HCC: Performance and novel refinements. Journal of Hepatology, 2020, 72, 288-306. | 1.8 | 292 |
| 249 | Novel patient-derived preclinical models of liver cancer. Journal of Hepatology, 2020, 72, 239-249. | 1.8 | 41 |
| 250 | Milestones in the pathogenesis and management of primary liver cancer. Journal of Hepatology, 2020, 72, 209-214. | 1.8 | 39 |
| 251 | Molecular therapies for HCC: Looking outside the box. Journal of Hepatology, 2020, 72, 342-352. | 1.8 | 250 |
| 252 | Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophysics Reports, 2020, 6, 19-32. | 0.2 | 1 |
| 253 | Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms. EBioMedicine, 2020, 52, 102644. | 2.7 | 8 |
| 254 | Long noncoding RNA TCL6 binds to miRâ€106aâ€5p to regulate hepatocellular carcinoma cells through PI3K/AKT signaling pathway. Journal of Cellular Physiology, 2020, 235, 6154-6166. | 2.0 | 26 |
| 255 | Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. Liver Cancer, 2020, 9, 426-439. | 4.2 | 26 |
| 256 | Serum STIP1, a Novel Indicator for Microvascular Invasion, Predicts Outcomes and Treatment Response in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 511. | 1.3 | 13 |
| 257 | ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis. Oncogenesis, 2020, 9, 42. | 2.1 | 48 |
| 258 | IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology, 2020, 16, 975-989. | 1.1 | 136 |

| # | Article | IF | Citations |
|---|---|---|---|
| 259 | Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma. Clinical and Experimental Medicine, 2020, 20, 329-337. | 1.9 | 12 |
| 260 | DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. Cancer Letters, 2020, 483, 87-97. | 3.2 | 31 |
| 261 | Synaptopodin-2 promotes hepatocellular carcinoma metastasis via calcineurin-induced nuclear-cytoplasmic translocation. Cancer Letters, 2020, 482, 8-18. | 3.2 | 10 |
| 262 | ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma. Npj Precision Oncology, 2020, 4, 7. | 2.3 | 43 |
| 263 | Immuneâ€related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. Journal of Cellular Physiology, 2020, 235, 9304-9316. | 2.0 | 92 |
| 264 | High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 4302-4312. | 3.2 | 10 |
| 265 | A superstable homogeneous lipiodol-ICG formulation for locoregional hepatocellular carcinoma treatment. Journal of Controlled Release, 2020, 323, 635-643. | 4.8 | 58 |
| 266 | Prognostic and predicted significance of Ubqln2 in patients with hepatocellular carcinoma. Cancer Medicine, 2020, 9, 4083-4094. | 1.3 | 4 |
| 267 | The role of long noncoding RNAs in hepatocellular carcinoma. Molecular Cancer, 2020, 19, 77. | 7.9 | 310 |
| 268 | Evaluation of X-Ray Repair Cross-Complementing Family Members as Potential Biomarkers for Predicting Progression and Prognosis in Hepatocellular Carcinoma. BioMed Research International, 2020, 2020, 1-11. | 0.9 | 5 |
| 269 | Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFÎ² Signaling. Cancer Research, 2020, 80, 1819-1832. | 0.4 | 17 |
| 270 | Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191. | 3.6 | 235 |
| 271 | Surgical Treatments of Hepatobiliary Cancers. Hepatology, 2021, 73, 128-136. | 3.6 | 99 |
| 272 | Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. Hepatology Research, 2021, 51, 5-18. | 1.8 | 29 |
| 273 | Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. Journal of Gastrointestinal Surgery, 2021, 25, 421-427. | 0.9 | 94 |
| 274 | Current status of systemic therapy in hepatocellular cancer. Digestive and Liver Disease, 2021, 53, 397-402. | 0.4 | 4 |
| 275 | Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacologica Sinica, 2021, 42, 301-310. | 2.8 | 147 |
| 276 | Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea. Investigational New Drugs, 2021, 39, 260-268. | 1.2 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 277 | Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut, 2021, 70, 204-214. | 6.1 | 150 |
| 278 | p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 96-108. | 1.8 | 54 |
| 279 | Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 377-389. | 2.0 | 25 |
| 280 | Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium. Hepatology, 2021, 73, 1736-1746. | 3.6 | 32 |
| 281 | An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 967-979. | 2.0 | 103 |
| 282 | Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A. Cellular Oncology (Dordrecht), 2021, 44, 329-343. | 2.1 | 17 |
| 283 | Proteomic analysis reveals critical molecular mechanisms involved in the macrophage anti-spinal tuberculosis process. Tuberculosis, 2021, 126, 102039. | 0.8 | 1 |
| 284 | Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. International Immunopharmacology, 2021, 90, 107164. | 1.7 | 15 |
| 285 | Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International, 2021, 41, 598-607. | 1.9 | 13 |
| 286 | Sophoridine suppresses lenvatinibâ€resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. Journal of Cellular and Molecular Medicine, 2021, 25, 549-560. | 1.6 | 41 |
| 287 | ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clinical Cancer Research, 2021, 27, 1150-1161. | 3.2 | 42 |
| 288 | Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells through TRIM44-STAT3 Signaling Pathway. Journal of Cancer, 2021, 12, 89-98. | 1.2 | 11 |
| 289 | Transarterial chemoembolisation enhances programmed deathâ€1 and programmed deathâ€ligand 1 expression in hepatocellular carcinoma. Histopathology, 2021, 79, 36-46. | 1.6 | 49 |
| 291 | Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. Molecular Therapy, 2021, 29, 680-690. | 3.7 | 61 |
| 292 | Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. European Radiology, 2021, 31, 2737-2746. | 2.3 | 8 |
| 293 | Nanoparticle-Loaded Polarized-Macrophages for Enhanced Tumor Targeting and Cell-Chemotherapy. Nano-Micro Letters, 2021, 13, 6. | 14.4 | 27 |
| 294 | Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 217-233. | 1.4 | 37 |
| 295 | Modulation of antioxidant enzymes, SIRT1 and NFâ€ºB by resveratrol and nicotinamide in alcoholâ€aflatoxin B1â€induced hepatocellular carcinoma. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22625. | 1.4 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 296 | A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. Journal of Cellular Physiology, 2021, 236, 2572-2591. | 2.0 | 26 |
| 297 | TM4SF1, a binding protein of DVL2 in hepatocellular carcinoma, positively regulates betaâ€catenin/TCF signalling. Journal of Cellular and Molecular Medicine, 2021, 25, 2356-2364. | 1.6 | 14 |
| 298 | Adding Sorafenib-eluting Microspheres to TACE: The Next Step in Hepatocellular Carcinoma Treatment. Radiology Imaging Cancer, 2021, 3, e200132. | 0.7 | 0 |
| 299 | Epidemiology, mutational landscape and staging of hepatocellular carcinoma. Chinese Clinical Oncology, 2021, 10, 2-2. | 0.4 | 9 |
| 300 | Three novel circRNAs upregulated in tissue and plasma from hepatocellular carcinoma patients and their regulatory network. Cancer Cell International, 2021, 21, 72. | 1.8 | 13 |
| 301 | Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1â€mediated EMT. Molecular Carcinogenesis, 2021, 60, 151-163. | 1.3 | 13 |
| 302 | Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer, 2021, 10, 85-93. | 4.2 | 22 |
| 303 | Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers, 2021, 13, 160. | 1.7 | 38 |
| 304 | Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 470-479. | 0.7 | 8 |
| 305 | Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management. Small, 2021, 17, e2005236. | 5.2 | 28 |
| 306 | Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treatment and Research Communications, 2021, 27, 100328. | 0.7 | 70 |
| 307 | Fluorescent Agâ€“Inâ€“S/ZnS Quantum Dots for Tumor Drainage Lymph Node Imaging In Vivo. ACS Applied Nano Materials, 2021, 4, 1029-1037. | 2.4 | 10 |
| 308 | Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma. Cells, 2021, 10, 123. | 1.8 | 28 |
| 309 | Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study. Oncology, 2021, 99, 641-651. | 0.9 | 9 |
| 310 | Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer. Bioscience Reports, 2021, 41, . | 1.1 | 6 |
| 311 | CLEC3B as a Potential Prognostic Biomarker in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2020, 7, 614034. | 1.6 | 10 |
| 312 | Multi-Disease Prediction Based on Deep Learning: A Survey. CMES - Computer Modeling in Engineering and Sciences, 2021, 128, 489-522. | 0.8 | 123 |
| 313 | Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma. Aging, 2021, 13, 4138-4156. | 1.4 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 314 | Research Progress in Targeted Therapy of Hepatocellular Carcinoma. Chinese Medical Sciences Journal, 2021, 36, 57-65. | 0.2 | 2 |
| 315 | Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma. Bioengineered, 2021, 12, 1202-1211. | 1.4 | 5 |
| 316 | Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. Journal of Cancer, 2021, 12, 2933-2951. | 1.2 | 18 |
| 317 | Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 574778. | 1.3 | 4 |
| 318 | Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study. Cancer Medicine, 2021, 10, 914-922. | 1.3 | 10 |
| 319 | Identification of potential biomarkers of peripheral blood mononuclear cell in hepatocellular carcinoma using bioinformatic analysis. Medicine (United States), 2021, 100, e24172. | 0.4 | 4 |
| 320 | The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treatment and Research Communications, 2021, 27, 100360. | 0.7 | 4 |
| 321 | TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1121-1143. | 2.3 | 10 |
| 322 | DLG1-AS1 is activated by MYC and drives the proliferation and migration of hepatocellular carcinoma cells through miR-497-5p/SSRP1 axis. Cancer Cell International, 2021, 21, 16. | 1.8 | 5 |
| 323 | Addition of apatinib to transarterial chemoembolization leads to improved outcome in patients with intermediate and advanced hepatocellular cancer. Annals of Translational Medicine, 2021, 9, 2-2. | 0.7 | 0 |
| 324 | The E-Twenty-Six Family in Hepatocellular Carcinoma: Moving into the Spotlight. Frontiers in Oncology, 2020, 10, 620352. | 1.3 | 0 |
| 325 | Organoids for the Study of Liver Cancer. Seminars in Liver Disease, 2021, 41, 019-027. | 1.8 | 8 |
| 326 | Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis. International Journal of Biological Sciences, 2021, 17, 220-235. | 2.6 | 27 |
| 327 | Molecular Carcinogenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma. , 2021, , 123-141. | | 0 |
| 328 | A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. Journal of Translational Medicine, 2021, 19, 5. | 1.8 | 66 |
| 329 | Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma. Bioengineered, 2021, 12, 673-681. | 1.4 | 10 |
| 330 | Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma. Food and Function, 2021, 12, 1482-1497. | 2.1 | 10 |
| 331 | MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating Î²â€catenin and predicts poor prognosis. Liver International, 2021, 41, 1409-1420. | 1.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 332 | Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL). Frontiers in Genetics, 2021, 12, 625414. | 1.1 | 8 |
| 334 | A novel multifunctional gold nanorod-mediated and tumor-targeted gene silencing of GPC-3 synergizes photothermal therapy for liver cancer. Nanotechnology, 2021, 32, 175101. | 1.3 | 8 |
| 335 | PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 607021. | 1.3 | 9 |
| 336 | A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity. Communications Biology, 2021, 4, 217. | 2.0 | 21 |
| 337 | A novel hypoxia gene signature indicates prognosis and immune microenvironments characters in patients with hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2021, 25, 3772-3784. | 1.6 | 15 |
| 338 | Role of liver sinusoidal endothelial cells in liver diseases. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 411-431. | 8.2 | 150 |
| 339 | Tumor Microenvironment Triggered Cascadeâ€Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma. Advanced Healthcare Materials, 2021, 10, e2002036. | 3.9 | 14 |
| 340 | Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British Journal of Cancer, 2021, 124, 1388-1397. | 2.9 | 39 |
| 341 | Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. Frontiers in Oncology, 2020, 10, 610513. | 1.3 | 17 |
| 342 | LXRÎ± activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nature Cancer, 2021, 2, 201-217. | 5.7 | 27 |
| 343 | Balanophorin B inhibited glycolysis with the involvement of HIF-1Î±. Life Sciences, 2021, 267, 118910. | 2.0 | 11 |
| 344 | Understanding relevant immune mechanisms in gastrointestinal oncology. Journal of Oncology Pharmacy Practice, 2021, 27, 107815522199286. | 0.5 | 0 |
| 345 | Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Frontiers in Oncology, 2020, 10, 605057. | 1.3 | 4 |
| 346 | Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. Journal of Experimental and Clinical Cancer Research, 2021, 40, 73. | 3.5 | 24 |
| 347 | FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. Cancers, 2021, 13, 1360. | 1.7 | 24 |
| 348 | Cell Division Cycle Associated Genes as Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 657161. | 1.6 | 6 |
| 349 | Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 652172. | 2.2 | 21 |
| 350 | Management of complex liver diseases. Minerva Gastroenterology, 2021, 67, 2-3. | 0.3 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 351 | Overexpression of Taspase 1 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Management and Research, 2021, Volume 13, 2517-2537. | 0.9 | 3 |
| 352 | Long nonâ€‘coding RNA ADAMTS9â€‘AS2 inhibits liver cancer cell proliferation, migration and invasion. Experimental and Therapeutic Medicine, 2021, 21, 559. | 0.8 | 14 |
| 353 | LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation. Oncogene, 2021, 40, 2581-2595. | 2.6 | 8 |
| 354 | The relationship among Girdin DNA methylation, its high expression, and immune infiltration in hepatocellular carcinoma: Clues from in silico analysis. Bioscience Reports, 2021, 41, . | 1.1 | 4 |
| 355 | An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients. Cancer Cell International, 2021, 21, 166. | 1.8 | 12 |
| 356 | Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells. Archives of Biochemistry and Biophysics, 2021, 699, 108754. | 1.4 | 12 |
| 357 | Hepatocellular carcinoma progression during bridging before liver transplantation. BJS Open, 2021, 5, . | 0.7 | 5 |
| 358 | Nuf2 Is a Prognostic-Related Biomarker and Correlated With Immune Infiltrates in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 621373. | 1.3 | 19 |
| 359 | Expression and prognostic rolesÂof PRDXs gene family in hepatocellular carcinoma. Journal of Translational Medicine, 2021, 19, 126. | 1.8 | 4 |
| 360 | Circulating Tumor Cells Undergoing the Epithelialâ€“Mesenchymal Transition: Influence on Prognosis in Cytokeratin 19-Positive Hepatocellular Carcinoma. OncoTargets and Therapy, 2021, Volume 14, 1543-1552. | 1.0 | 7 |
| 362 | Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. Minerva Gastroenterology, 2021, 67, . | 0.3 | 7 |
| 363 | circFOXM1 contributes to sorafenib resistance of hepatocellular carcinoma cells by regulating MECP2 via miR-1324. Molecular Therapy - Nucleic Acids, 2021, 23, 811-820. | 2.3 | 30 |
| 364 | 4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice. Scientific Reports, 2021, 11, 6310. | 1.6 | 13 |
| 365 | Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma. British Journal of Radiology, 2021, 94, 20200950. | 1.0 | 18 |
| 366 | Nujiangexanthone A Inhibits Hepatocellular Carcinoma Metastasis via Down Regulation of Cofilin 1. Frontiers in Cell and Developmental Biology, 2021, 9, 644716. | 1.8 | 4 |
| 367 | Novel Ferrocene Derivatives Induce G0/G1 Cell Cycle Arrest and Apoptosis through the Mitochondrial Pathway in Human Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 3097. | 1.8 | 6 |
| 368 | Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. International Immunopharmacology, 2021, 92, 107333. | 1.7 | 62 |
| 369 | Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. Aging, 2021, 13, 11564-11594. | 1.4 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 370 | Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages. Annals of Surgical Oncology, 2021, 28, 7647-7660. | 0.7 | 6 |
| 371 | Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity. Cells, 2021, 10, 869. | 1.8 | 12 |
| 372 | GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death and Disease, 2021, 12, 426. | 2.7 | 152 |
| 373 | Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway. Frontiers in Oncology, 2021, 11, 659676. | 1.3 | 15 |
| 374 | Circular RNA hsa_circ_0013958 Functions as an Oncogenic Gene Through Modulating miR-532-3p/WEE1 Axis in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 585172. | 1.3 | 1 |
| 375 | From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. Cancers, 2021, 13, 2024. | 1.7 | 5 |
| 376 | AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. American Journal of Physiology - Renal Physiology, 2021, 320, G543-G556. | 1.6 | 5 |
| 377 | Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 645084. | 1.6 | 27 |
| 378 | Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review). Cancer Biology and Therapy, 2021, 22, 279-290. | 1.5 | 11 |
| 379 | Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Frontiers in Immunology, 2021, 12, 643310. | 2.2 | 27 |
| 380 | AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers. Frontiers in Cell and Developmental Biology, 2021, 9, 635476. | 1.8 | 9 |
| 381 | Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance. Current Medicinal Chemistry, 2021, 28, 1126-1142. | 1.2 | 19 |
| 382 | Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma. Pharmacological Research, 2021, 166, 105507. | 3.1 | 28 |
| 383 | KDM5B promotes selfâ€renewal of hepatocellular carcinoma cells through the microRNAâ€448â€“mediated YTHDF3/ITGA6 axis. Journal of Cellular and Molecular Medicine, 2021, 25, 5949-5962. | 1.6 | 21 |
| 384 | Dysregulation of Wnt/Î²â€catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application. Cancer Science, 2021, 112, 1695-1706. | 1.7 | 30 |
| 385 | Development of biparatopic bispecific antibody possessing tetravalent scFv-Fc capable of binding to ROBO1 expressed in hepatocellular carcinoma cells. Journal of Biochemistry, 2021, 170, 307-315. | 0.9 | 3 |
| 386 | SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma. Cancer Biomarkers, 2021, 32, 425-433. | 0.8 | 15 |
| 387 | Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. BMC Cancer, 2021, 21, 376. | 1.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 388 | Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma. Cancer Cell International, 2021, 21, 190. | 1.8 | 15 |
| 389 | Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Panminerva Medica, 2021, , . | 0.2 | 2 |
| 390 | Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response. Abdominal Radiology, 2021, 46, 3674-3685. | 1.0 | 16 |
| 391 | Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma. Cancers, 2021, 13, 2182. | 1.7 | 4 |
| 392 | Amplification of DDR2 mediates sorafenib resistance through NFâ€ÎºB/câ€Rel signaling in hepatocellular carcinoma. Cell Biology International, 2021, 45, 1906-1916. | 1.4 | 8 |
| 393 | eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma. Anti-Cancer Drugs, 2021, 32, 822-828. | 0.7 | 7 |
| 394 | The Crosstalk Between Cancer Cells and Neutrophils Enhances Hepatocellular Carcinoma Metastasis via Neutrophil Extracellular Traps-Associated Cathepsin G Component: A Potential Therapeutic Target. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 451-465. | 1.8 | 43 |
| 396 | PHAROH lncRNA regulates Myc translation in hepatocellular carcinoma via sequestering TIAR. ELife, 2021, 10, . | 2.8 | 18 |
| 397 | Circular RNA hsa_circ_0091579 facilitates the Warburg effect and malignancy of hepatocellular carcinoma cells via the miR-624/H3F3B axis. Clinical and Translational Oncology, 2021, 23, 2280-2292. | 1.2 | 6 |
| 398 | The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers, 2021, 13, 2621. | 1.7 | 15 |
| 399 | Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Scientific Reports, 2021, 11, 9587. | 1.6 | 10 |
| 400 | Trilostane, a 3Î²-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib. Investigational New Drugs, 2021, 39, 1493-1506. | 1.2 | 5 |
| 401 | BMP9â€ÐD1 signaling promotes EpCAMâ€positive cancer stem cell properties in hepatocellular carcinoma. Molecular Oncology, 2021, 15, 2203-2218. | 2.1 | 14 |
| 402 | Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1. Aging, 2021, 13, 20094-20115. | 1.4 | 16 |
| 403 | Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission. Journal of Pain and Symptom Management, 2021, 61, 940-947.e3. | 0.6 | 10 |
| 404 | Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells. Oncology Letters, 2021, 22, 546. | 0.8 | 9 |
| 405 | Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma. Investigational New Drugs, 2021, 39, 1439-1453. | 1.2 | 11 |
| 406 | Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. International Journal of Molecular Sciences, 2021, 22, 5801. | 1.8 | 182 |

| # | Article | IF | Citations |
|---|---|---|---|
| 407 | Texture Analysis Based on Gd-EOB-DTPA-Enhanced MRI for Identifying Vessels Encapsulating Tumor Clusters (VETC)-Positive Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 349-359. | 1.8 | 14 |
| 408 | CD147 Monoclonal Antibody Targeted Reduction-Responsive Camptothecin Polyphosphoester Nanomedicine for Drug Delivery in Hepatocellular Carcinoma Cells. ACS Applied Bio Materials, 2021, 4, 4422-4431. | 2.3 | 17 |
| 409 | Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 683240. | 1.6 | 14 |
| 410 | Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina ClÃnica (English Edition), 2021, 156, 463.e1-463.e30. | 0.1 | 16 |
| 411 | Inhibition effects of 7-phloro-eckol from Ecklonia cava on metastasis and angiogenesis induced by hypoxia through regulation of AKT/mTOR and ERK signaling pathways. Arabian Journal of Chemistry, 2021, 14, 103187. | 2.3 | 9 |
| 412 | Exploring liver cancer biology through functional genetic screens. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 690-704. | 8.2 | 31 |
| 413 | Co-amplification of genes in chromosome 8q24: a robust prognostic marker in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2021, 12, 1086-1100. | 0.6 | 2 |
| 414 | SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC. Molecular Therapy - Oncolytics, 2021, 21, 264-277. | 2.0 | 30 |
| 415 | Development and validation of ferroptosis-related lncRNAs signature for hepatocellular carcinoma. PeerJ, 2021, 9, e11627. | 0.9 | 22 |
| 416 | Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structureâ€“Activity Relationship Analysis. Journal of Medicinal Chemistry, 2021, 64, 8992-9009. | 2.9 | 5 |
| 417 | Whole-transcriptome and proteome analyses identify key differentially expressed mRNAs, miRNAs, lncRNAs and circRNAs associated with HCC. Oncogene, 2021, 40, 4820-4831. | 2.6 | 14 |
| 418 | Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nature Communications, 2021, 12, 3684. | 5.8 | 136 |
| 419 | Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy, 2021, 13, 637-644. | 1.0 | 63 |
| 420 | Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects. Frontiers in Oncology, 2021, 11, 670838. | 1.3 | 6 |
| 421 | New Molecular Mechanisms and Clinical Impact of circRNAs in Human Cancer. Cancers, 2021, 13, 3154. | 1.7 | 50 |
| 422 | YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition. Experimental Hematology and Oncology, 2021, 10, 35. | 2.0 | 54 |
| 423 | The therapeutic effect of IL-21 combined with IFN-Î³ inducing CD4+CXCR5+CD57+T cells differentiation on hepatocellular carcinoma. Journal of Advanced Research, 2021, 36, 89-99. | 4.4 | 3 |
| 424 | Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. Journal of Drug Delivery Science and Technology, 2021, 63, 102493. | 1.4 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 425 | Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma. Scientific Reports, 2021, 11, 12097. | 1.6 | 8 |
| 426 | Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 6401. | 1.8 | 7 |
| 427 | Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma. Biochemical Pharmacology, 2021, 188, 114494. | 2.0 | 5 |
| 428 | m6A RNA Methylation Regulators Elicit Malignant Progression and Predict Clinical Outcome in Hepatocellular Carcinoma. Disease Markers, 2021, 2021, 1-12. | 0.6 | 4 |
| 429 | Multiparametric Analyses of Hepatocellular Carcinoma Somatic Mouse Models and Their Associated Tumor Microenvironment. Current Protocols, 2021, 1, e147. | 1.3 | 5 |
| 430 | Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. Expert Opinion on Investigational Drugs, 2022, 31, 371-378. | 1.9 | 65 |
| 431 | Identifying the biomarkers and pathways associated with hepatocellular carcinoma based on an integrated analysis approach. Liver International, 2021, 41, 2485-2498. | 1.9 | 2 |
| 432 | DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Aging, 2021, 13, 17592-17606. | 1.4 | 8 |
| 433 | Global analysis of gene expression signature and diagnostic/prognostic biomarker identification of hepatocellular carcinoma. Science Progress, 2021, 104, 003685042110294. | 1.0 | 8 |
| 434 | Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World Journal of Clinical Cases, 2021, 9, 5988-5998. | 0.3 | 2 |
| 435 | Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treatment Reviews, 2021, 98, 102221. | 3.4 | 43 |
| 436 | Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Journal of Clinical Medicine, 2021, 10, 3201. | 1.0 | 13 |
| 437 | How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers, 2021, 13, 3536. | 1.7 | 4 |
| 438 | Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma. Molecular Medicine Reports, 2021, 24, . | 1.1 | 13 |
| 439 | Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. Cancers, 2021, 13, 3633. | 1.7 | 10 |
| 440 | Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine, 2021, 87, 153575. | 2.3 | 41 |
| 441 | Transcriptome analysis of signaling pathways targeted by Ellagic acid in hepatocellular carcinoma cells. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129911. | 1.1 | 6 |
| 442 | Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 4453-4467. | 1.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 443 | The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1195-1210. | 1.2 | 8 |
| 444 | Exploiting lipotoxicity for the treatment of liver cancer. British Journal of Cancer, 2021, 125, 1459-1461. | 2.9 | 2 |
| 445 | Prognostic Role and Potential Mechanisms of N6-methyladenosine-related Long Noncoding RNAs in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2022, 10, 308-320. | 0.7 | 4 |
| 446 | Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. JGH Open, 2021, 5, 864-870. | 0.7 | 1 |
| 447 | High expression of PPM1G is associated with the progression and poor prognosis of hepatocellular carcinoma. Cancer Biomarkers, 2022, 34, 13-22. | 0.8 | 4 |
| 448 | Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. Journal of Chemotherapy, 2022, 34, 286-301. | 0.7 | 4 |
| 449 | Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1-12. | 0.9 | 2 |
| 450 | Advances of Targeted Therapy for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 719896. | 1.3 | 23 |
| 451 | PLEKHA8P1 Promotes Tumor Progression and Indicates Poor Prognosis of Liver Cancer. International Journal of Molecular Sciences, 2021, 22, 7614. | 1.8 | 7 |
| 452 | N2E4, a Monoclonal Antibody Targeting Neuropilin-2, Inhibits Tumor Growth and Metastasis in Pancreatic Ductal Adenocarcinoma via Suppressing FAK/Erk/HIF-1Î± Signaling. Frontiers in Oncology, 2021, 11, 657008. | 1.3 | 12 |
| 453 | Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?. Gut and Liver, 2021, 15, 500-516. | 1.4 | 36 |
| 454 | The Liver and the Hepatic Immune Response in Trypanosoma cruzi Infection, a Historical and Updated View. Pathogens, 2021, 10, 1074. | 1.2 | 8 |
| 455 | Molecular Targets of Ferroptosis in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 985-996. | 1.8 | 17 |
| 456 | Machine Learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma After Surgical Resection. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 913-923. | 1.8 | 11 |
| 457 | METTL3â€mediated m6A methylation of ASPM drives hepatocellular carcinoma cells growth and metastasis. Journal of Clinical Laboratory Analysis, 2021, 35, e23931. | 0.9 | 10 |
| 458 | Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magnetic Resonance Imaging Clinics of North America, 2021, 29, 389-403. | 0.6 | 3 |
| 459 | Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 669145. | 1.8 | 8 |
| 460 | MRI-Radiomics Prediction for Cytokeratin 19-Positive Hepatocellular Carcinoma: A Multicenter Study. Frontiers in Oncology, 2021, 11, 672126. | 1.3 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 461 | DUSP12 regulates the tumorigenesis and prognosis of hepatocellular carcinoma. PeerJ, 2021, 9, e11929. | 0.9 | 4 |
| 462 | Mild chronic hypoxia-induced HIF-2Î± interacts with c-MYC through competition with HIF-1Î± to induce hepatocellular carcinoma cell proliferation. Cellular Oncology (Dordrecht), 2021, 44, 1151-1166. | 2.1 | 9 |
| 463 | First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1245-1251. | 1.4 | 75 |
| 464 | Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report. Diagnostics, 2021, 11, 1394. | 1.3 | 1 |
| 465 | Comprehensive Analyses of the Infiltrating Immune Cell Landscape and Its Clinical Significance in Hepatocellular Carcinoma. International Journal of General Medicine, 2021, Volume 14, 4695-4704. | 0.8 | 7 |
| 466 | Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma. Cancer Management and Research, 2021, Volume 13, 6451-6471. | 0.9 | 16 |
| 467 | N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World Journal of Surgical Oncology, 2021, 19, 241. | 0.8 | 13 |
| 468 | Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomarker Research, 2021, 9, 64. | 2.8 | 13 |
| 469 | Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapy. Cell Biology International, 2021, 45, 2161-2177. | 1.4 | 11 |
| 470 | Intrinsic activation of Î²-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma. Scientific Reports, 2021, 11, 16732. | 1.6 | 10 |
| 471 | Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1153-1165. | 1.4 | 13 |
| 472 | Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1Î± Expression. Digestive Diseases and Sciences, 2021, , 1. | 1.1 | 3 |
| 473 | LncRNA CRNDE Promotes ATG4B-Mediated Autophagy and Alleviates the Sensitivity of Sorafenib in Hepatocellular Carcinoma Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 687524. | 1.8 | 16 |
| 474 | Lentinan as a natural stabilizer with bioactivities for preparation of drugâ€“drug nanosuspensions. International Journal of Biological Macromolecules, 2021, 184, 101-108. | 3.6 | 18 |
| 475 | Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000. | 0.7 | 4 |
| 476 | Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 615-628. | 4.2 | 31 |
| 477 | Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 997-1021. | 1.8 | 11 |
| 478 | Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer. Journal of Hematology and Oncology, 2021, 14, 134. | 6.9 | 70 |

| # | Article | IF | Citations |
|---|---|---|---|
| 479 | KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma. International Journal of Biochemistry and Cell Biology, 2021, 137, 106037. | 1.2 | 3 |
| 480 | YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. Hepatology, 2021, 74, 2605-2621. | 3.6 | 22 |
| 481 | RAB27Aâ€dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3429-3437. | 1.4 | 19 |
| 482 | Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 9044. | 1.8 | 7 |
| 483 | PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. Expert Opinion on Investigational Drugs, 2022, 31, 415-423. | 1.9 | 78 |
| 484 | Biocompatible zinc gallogermanate persistent luminescent nanoparticles for fast tumor drainage lymph node imaging in vivo. Colloids and Surfaces B: Biointerfaces, 2021, 205, 111887. | 2.5 | 4 |
| 485 | AGTRAP Is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 713017. | 1.3 | 5 |
| 486 | Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma. Bioscience Reports, 2021, 41, . | 1.1 | 1 |
| 488 | Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma. Frontiers in Medicine, 2021, 8, 754709. | 1.2 | 7 |
| 489 | Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311. | | 66 |
| 490 | Integrated Analysis and Finding Reveal Antiâ€“Liver Cancer Targets and Mechanisms of Pachyman (Poria) Tj ETQq0 0 0 rgBT /Overlock 1 | 1.6 | 15 |
| 491 | Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer, 2021, 10, 561-571. | 4.2 | 11 |
| 492 | Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma. Cancer Cell International, 2021, 21, 475. | 1.8 | 8 |
| 493 | Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2021, , 1. | 1.2 | 3 |
| 494 | A novel prognostic signature based on four glycolysisâ€related genes predicts survival and clinical risk of hepatocellular carcinoma. Journal of Clinical Laboratory Analysis, 2021, 35, e24005. | 0.9 | 10 |
| 496 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794. | | 43 |
| 497 | LncAY controls BMI1 expression and activates BMI1/Wnt/Î²-catenin signaling axis in hepatocellular carcinoma. Life Sciences, 2021, 280, 119748. | 2.0 | 20 |
| 499 | Microscopic Portal Vein Invasion in Relation to Tumor Focality and Dimension in Patients with Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2022, 26, 333-340. | 0.9 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 500 | Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opinion on Therapeutic Targets, 2021, 25, 645-658. | 1.5 | 5 |
| 501 | Toward Personalized Medicine in Radiotherapy of Hepatocellular Carcinoma: Emerging Radiomic Biomarker Candidates of Response and Toxicity. OMICS A Journal of Integrative Biology, 2021, 25, 537-544. | 1.0 | 2 |
| 502 | The Prognostic Model Based on Tumor Cell Evolution Trajectory Reveals a Different Risk Group of Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 737723. | 1.8 | 3 |
| 503 | Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 736330. | 1.6 | 10 |
| 504 | Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway. Journal of Experimental and Clinical Cancer Research, 2021, 40, 280. | 3.5 | 10 |
| 505 | Decitabine-Loaded Gold Nanocages for Photothermal Cancer Therapy via DNA Hypermethylation Reversal. ACS Applied Nano Materials, 2021, 4, 10556-10564. | 2.4 | 7 |
| 506 | The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Frontiers in Oncology, 2021, 11, 635731. | 1.3 | 26 |
| 507 | Great future or greedy venture: Precision medicine needs philosophy. Health Science Reports, 2021, 4, e376. | 0.6 | 1 |
| 508 | Deficiency of GFRÎ±1 promotes hepatocellular carcinoma progression but enhances oxaliplatin-mediated anti-tumor efficacy. Pharmacological Research, 2021, 172, 105815. | 3.1 | 2 |
| 509 | YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS. Frontiers in Pharmacology, 2021, 12, 744578. | 1.6 | 13 |
| 510 | Disminuyendo la heterogeneidad en hepatocarcinoma. AnÃ¡lisis de clÃºster por variables clÃnicas en pacientes atendidos en una instituciÃ³n de cuarto nivel de complejidad. Revista De GastroenterologÃa De MÃ©xico, 2021, 86, 356-362. | 0.4 | 3 |
| 511 | Deubiquitination of the repressor E2F6 by USP22 facilitates AKT activation and tumor growth in hepatocellular carcinoma. Cancer Letters, 2021, 518, 266-277. | 3.2 | 11 |
| 512 | Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 75, 865-878. | 1.8 | 111 |
| 513 | Reducing the heterogeneity in hepatocellular carcinoma. A cluster analysis based on clinical variables in patients treated at a quaternary care hospital. Revista De GastroenterologÃa De MÃ©xico (English) Tj ETQq1 1 0.784314 rgBT /Ove | 0.7 | |
| 514 | Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. Cancer Letters, 2021, 521, 210-223. | 3.2 | 20 |
| 515 | Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor. Materials and Design, 2021, 209, 109958. | 3.3 | 8 |
| 516 | Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166267. | 1.8 | 11 |
| 517 | Cancer cell-intrinsic STING is associated with CD8â€‰+â€‰T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma. Clinical and Translational Oncology, 2021, 23, 1314-1324. | 1.2 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 518 | miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. Annals of Translational Medicine, 2021, 9, 38-38. | 0.7 | 14 |
| 519 | Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics, 2021, 11, 3489-3501. | 4.6 | 35 |
| 520 | PAQR4 promotes the development of hepatocellular carcinoma by activating PI3K/AKT pathway. Acta Biochimica Et Biophysica Sinica, 2021, 53, 1602-1613. | 0.9 | 12 |
| 521 | BRD7 inhibits tumor progression by positively regulating the p53 pathway in hepatocellular carcinoma. Journal of Cancer, 2021, 12, 1507-1519. | 1.2 | 8 |
| 522 | Predicting HCC Response to Multikinase Inhibitors With InÂVivo Cirrhotic Mouse Model for Personalized Therapy. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1313-1325. | 2.3 | 12 |
| 523 | Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 293-313. | 8.2 | 428 |
| 524 | Electrochemical aptasensors for the detection of hepatocellular carcinoma-related biomarkers. New Journal of Chemistry, 2021, 45, 15158-15169. | 1.4 | 2 |
| 525 | Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma. Clinical Cancer Research, 2021, 27, 1827-1829. | 3.2 | 9 |
| 526 | Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6. | 18.1 | 2,757 |
| 527 | Immune Checkpoint Inhibitors in the Treatment of HCC. Frontiers in Oncology, 2020, 10, 601240. | 1.3 | 77 |
| 528 | Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management. Journal of Oncology, 2021, 2021, 1-20. | 0.6 | 26 |
| 529 | Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer, 2021, 10, 451-460. | 4.2 | 5 |
| 530 | Internet of Things for Sustainable Human Health. Internet of Things, 2020, , 217-242. | 1.3 | 18 |
| 531 | CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduction and Targeted Therapy, 2020, 5, 298. | 7.1 | 225 |
| 532 | MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression. Bioscience Reports, 2020, 40, . | 1.1 | 19 |
| 533 | Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma. Bioscience Reports, 2020, 40, . | 1.1 | 5 |
| 534 | Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma. Bioscience Reports, 2020, 40, . | 1.1 | 5 |
| 535 | Transplant Oncology in Primary and Metastatic Liver Tumors. Annals of Surgery, 2021, 273, 483-493. | 2.1 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 536 | Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer, 2020, 9, 640-662. | 4.2 | 78 |
| 537 | Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2020, 38, 1081. | 0.8 | 101 |
| 539 | Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells. Medical Science Monitor, 2019, 25, 5823-5832. | 0.5 | 22 |
| 540 | The Expression of Dynamin 1, 2, and 3 in Human Hepatocellular Carcinoma and Patient Prognosis. Medical Science Monitor, 2020, 26, e923359. | 0.5 | 5 |
| 541 | Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 is a diagnostic and prognostic biomarker for hepatocellular carcinoma. World Journal of Clinical Cases, 2020, 8, 3774-3785. | 0.3 | 1 |
| 543 | Tadalafil inhibits elevated glutamic oxaloacetic transaminase during alcohol aflatoxin induced hepatocellular carcinoma in rats. International Journal of Immunotherapy and Cancer Research, 2020, 6, 010-013. | 0.4 | 3 |
| 544 | CBX3/HP1Î³ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma. Aging, 2019, 11, 5483-5497. | 1.4 | 45 |
| 545 | New landscapes and horizons in hepatocellular carcinoma therapy. Aging, 2020, 12, 3053-3094. | 1.4 | 37 |
| 546 | RP11-295G20.2 facilitates hepatocellular carcinoma progression via the miR-6884-3p/CCNB1 pathway. Aging, 2020, 12, 14918-14932. | 1.4 | 8 |
| 547 | Alterations in TGF-Î² signaling leads to high HMGA2 levels potentially through modulation of PJA1/SMAD3 in HCC cells. Genes and Cancer, 2020, 11, 43-52. | 0.6 | 8 |
| 548 | Dysregulated PJA1-TGF-Î² signaling in cancer stem cell-associated liver cancers. Oncoscience, 2020, 7, 88-95. | 0.9 | 9 |
| 549 | Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Current Medicinal Chemistry, 2020, 27, 3290-3301. | 1.2 | 5 |
| 550 | Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma. Current Medicinal Chemistry, 2020, 27, 4789-4805. | 1.2 | 6 |
| 551 | Long Intergenic Non-Protein Coding RNA 665 Regulates Viability, Apoptosis, and Autophagy via the MiR-186-5p/MAP4K3 Axis in Hepatocellular Carcinoma. Yonsei Medical Journal, 2019, 60, 842. | 0.9 | 51 |
| 552 | Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences, 2021, 22, 224. | 1.8 | 22 |
| 553 | Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018. World Journal of Gastroenterology, 2019, 25, 4749-4763. | 1.4 | 13 |
| 554 | Role of liver biopsy in hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 6041-6052. | 1.4 | 92 |
| 555 | Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment. World Journal of Gastroenterology, 2020, 26, 2126-2137. | 1.4 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 556 | Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies. World Journal of Gastroenterology, 2020, 26, 3720-3736. | 1.4 | 32 |
| 557 | Efficacy and safety of drugâ€‘eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma. Experimental and Therapeutic Medicine, 2019, 18, 4625-4630. | 0.8 | 5 |
| 558 | Lenvatinib prolongs the progressionâ€‘free survival time of patients with intermediateâ€‘stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncology Letters, 2020, 20, 2257-2265. | 0.8 | 44 |
| 559 | Increased fibrillarin expression is associated with tumor progression and an unfavorable prognosis in hepatocellular carcinoma. Oncology Letters, 2020, 21, 92. | 0.8 | 14 |
| 560 | Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway. Biomolecules and Therapeutics, 2020, 28, 443-455. | 1.1 | 32 |
| 561 | FOS-like antigen 1 is a prognostic biomarker in hepatocellular carcinoma. Saudi Journal of Gastroenterology, 2019, 25, 369-376. | 0.5 | 11 |
| 562 | Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2019, 11, 788-803. | 0.8 | 8 |
| 563 | Blood exosomal micro ribonucleic acid profiling reveals the complexity of hepatocellular carcinoma and identifies potential biomarkers for differential diagnosis. World Journal of Gastrointestinal Oncology, 2020, 12, 1195-1208. | 0.8 | 7 |
| 564 | Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. World Journal of Hepatology, 2020, 12, 1211-1227. | 0.8 | 12 |
| 565 | Transcriptome analysis revealed key prognostic genes and microRNAs in hepatocellular carcinoma. PeerJ, 2020, 8, e8930. | 0.9 | 26 |
| 566 | Exploring the Expression and Prognostic Value of the TCP1 Ring Complex in Hepatocellular Carcinoma and Overexpressing Its Subunit 5 Promotes HCC Tumorigenesis. Frontiers in Oncology, 2021, 11, 739660. | 1.3 | 11 |
| 568 | MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy. Academic Radiology, 2022, 29, 819-829. | 1.3 | 8 |
| 569 | Nutritional therapy for hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 1440-1452. | 0.8 | 14 |
| 570 | Induction of Apoptosis by Isoalantolactone in Human Hepatocellular Carcinoma Hep3B Cells through Activation of the ROS-Dependent JNK Signaling Pathway. Pharmaceutics, 2021, 13, 1627. | 2.0 | 14 |
| 571 | Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1233-1240. | 1.8 | 71 |
| 572 | Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. Pharmaceutics, 2021, 13, 1631. | 2.0 | 8 |
| 573 | Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell Death and Disease, 2021, 12, 920. | 2.7 | 13 |
| 574 | Engineering nanotheranostic strategies for liver cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 1213-1228. | 0.8 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 575 | Optimizing outcomes in HCC: Comment on â€œoptimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysisâ€•by Jiang etÂal.. Translational Oncology, 2021, 14, 101246. | 1.7 | 0 |
| 577 | Second-line treatment of hepatocellular carcinoma: from theory to practical issues. Meditsinskiy Sovet, 2019, , 30-36. | 0.1 | 2 |
| 580 | Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies. Frontiers in Cell and Developmental Biology, 2021, 9, 777007. | 1.8 | 9 |
| 581 | Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers, 2021, 13, 5448. | 1.7 | 5 |
| 582 | Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening. Frontiers in Pharmacology, 2021, 12, 658197. | 1.6 | 10 |
| 583 | Clinical M2 macrophages-related genes to aid therapy in pancreatic ductal adenocarcinoma. Cancer Cell International, 2021, 21, 582. | 1.8 | 5 |
| 584 | Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. Cancer Letters, 2022, 525, 115-130. | 3.2 | 19 |
| 585 | Connective Tissue Growth Factor in Digestive System Cancers: A Review and Meta-Analysis. BioMed Research International, 2020, 2020, 1-10. | 0.9 | 2 |
| 586 | Hepatocellular carcinoma: update on treatment guidelines. Gastrointestinal Nursing, 2020, 18, S18-S26. | 0.0 | 1 |
| 587 | Three new 3-formyl-2-arylbenzofurans from Itea yunnanensis and their anti-hepatocellular carcinoma effects. Natural Product Research, 2022, 36, 1205-1214. | 1.0 | 8 |
| 589 | Radiolabeled Peptide Probes for Liver Cancer Imaging. Current Medicinal Chemistry, 2020, 27, 6968-6986. | 1.2 | 8 |
| 590 | WGCNA and LASSO algorithm constructed an immune infiltration-related 5-gene signature and nomogram to improve prognosis prediction of hepatocellular carcinoma. Biocell, 2022, 46, 401-415. | 0.4 | 5 |
| 591 | Successful stories of drug repurposing for cancer therapy in hepatocellular carcinoma. , 2020, , 213-229. | | 4 |
| 593 | Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series. Hepatoma Research, 2020, 2020, . | 0.6 | 1 |
| 594 | Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma. Frontiers of Medicine, 2022, 16, 467-482. | 1.5 | 4 |
| 595 | Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus, 2021, 13, e19274. | 0.2 | 32 |
| 596 | Elevated Neddylation Pathway Promotes Th2 Cells Infiltration by Transactivating STAT5A in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 709170. | 1.3 | 6 |
| 597 | CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1323-1338. | 1.8 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 599 | Evaluation of diagnostic accuracy of serum calcium channel Î±2Î´1 subunit in hepatocellular carcinoma-related cirrhosis. Egyptian Liver Journal, 2020, 10, . | 0.3 | 0 |
| 600 | Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling. Current Cancer Drug Targets, 2020, 20, 779-788. | 0.8 | 10 |
| 601 | EYA1 promotes cell migration and tumor metastasis in hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2019, 11, 2328-2338. | 0.0 | 5 |
| 602 | New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies. American Journal of Cancer Research, 2019, 9, 1329-1353. | 1.4 | 25 |
| 603 | SPP1 functions as an enhancer of cell growth in hepatocellular carcinoma targeted by miR-181c. American Journal of Translational Research (discontinued), 2019, 11, 6924-6937. | 0.0 | 20 |
| 604 | Betulinic acid induces autophagy-mediated apoptosis through suppression of the PI3K/AKT/mTOR signaling pathway and inhibits hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2019, 11, 6952-6964. | 0.0 | 14 |
| 605 | Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 1522-1533. | 1.4 | 4 |
| 606 | Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial. American Journal of Cancer Research, 2020, 10, 1467-1476. | 1.4 | 1 |
| 607 | BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K. American Journal of Cancer Research, 2020, 10, 1900-1918. | 1.4 | 2 |
| 608 | Identifying drug candidates for hepatocellular carcinoma based on differentially expressed genes. American Journal of Translational Research (discontinued), 2020, 12, 2664-2674. | 0.0 | 0 |
| 609 | Low expression of NTF3 is associated with unfavorable prognosis in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 2280-2288. | 0.5 | 1 |
| 610 | Development and validation of a survival model based on autophagy-associated genes for predicting prognosis of hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 6705-6722. | 0.0 | 3 |
| 611 | microRNA-219-5p targets NEK6 to inhibit hepatocellular carcinoma progression. American Journal of Translational Research (discontinued), 2020, 12, 7528-7541. | 0.0 | 3 |
| 612 | Silencing reverses acquired resistance to sorafenib in hepatocellular carcinoma. Aging, 2020, 12, 22975-23003. | 1.4 | 0 |
| 613 | A Immune-Related Signature Associated with TME Can Serve as a Potential Biomarker for Survival and Sorafenib Resistance in Liver Cancer. OncoTargets and Therapy, 2021, 14, 5065-5083. | 1.0 | 3 |
| 614 | Arsenite-loaded albumin nanoparticles for targeted synergistic chemo-photothermal therapy of HCC. Biomaterials Science, 2021, 10, 243-257. | 2.6 | 11 |
| 615 | Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells. Cell Death and Disease, 2021, 12, 1073. | 2.7 | 9 |
| 616 | Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma. Cancers, 2021, 13, 6029. | 1.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 617 | Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene. Journal of Personalized Medicine, 2021, 11, 1199. | 1.1 | 4 |
| 618 | Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. Frontiers in Genetics, 2021, 12, 717319. | 1.1 | 10 |
| 619 | LncSNHG3 promotes hepatocellular carcinoma epithelial mesenchymal transition progression through the miR-152-3p/JAK1 pathway. Genes and Genomics, 2021, , 1. | 0.5 | 1 |
| 620 | A Combination of Blood Lymphocytes and AST Levels Distinguishes Patients with Small Hepatocellular Carcinomas from Non-cancer Patients. Journal of Gastrointestinal Cancer, 2021, 52, 1211-1216. | 0.6 | 3 |
| 621 | Wnt/Î²-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1415-1444. | 1.8 | 65 |
| 622 | Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2022, 19, 151-172. | 12.5 | 643 |
| 623 | Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. Journal of Experimental and Clinical Cancer Research, 2021, 40, 364. | 3.5 | 15 |
| 624 | Development and Validation of a Pyroptosis-Related Long Non-coding RNA Signature for Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 713925. | 1.8 | 36 |
| 625 | PRRC2A Promotes Hepatocellular Carcinoma Progression and Associates with Immune Infiltration. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1495-1511. | 1.8 | 15 |
| 626 | Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy. Translational Cancer Research, 2021, 11, 0-0. | 0.4 | 5 |
| 627 | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 628 | Exosome-based rare earth nanoparticles for targetedin situand metastatic tumor imaging with chemo-assisted immunotherapy. Biomaterials Science, 2022, 10, 744-752. | 2.6 | 5 |
| 629 | Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues. Proteomics, 2021, , 2100141. | 1.3 | 0 |
| 630 | MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1. Cell Death and Disease, 2022, 13, 35. | 2.7 | 22 |
| 631 | Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib. Malignant Tumours, 2022, 11, 45-52. | 0.1 | 1 |
| 632 | Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy. Frontiers in Pharmacology, 2021, 12, 809125. | 1.6 | 3 |
| 633 | Silencing <italic>KIF14</italic> reverses acquired resistance to sorafenib in hepatocellular carcinoma. Aging, 2020, 12, 22975-23003. | 1.4 | 6 |
| 634 | A Immune-Related Signature Associated with TME Can Serve as a Potential Biomarker for Survival and Sorafenib Resistance in Liver Cancer. OncoTargets and Therapy, 2021, Volume 14, 5065-5083. | 1.0 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 635 | Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. Annals of Hepatology, 2022, 27, 100677. | 0.6 | 5 |
| 636 | Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered, 2022, 13, 3108-3121. | 1.4 | 20 |
| 637 | Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. Science Advances, 2022, 8, eabh2635. | 4.7 | 35 |
| 638 | A Prognostic Nomogram for Hepatocellular Carcinoma Based on Wound Healing and Immune Checkpoint Genes. Journal of Clinical and Translational Hepatology, 2022, 10, 891-900. | 0.7 | 2 |
| 639 | Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. International Journal of Molecular Sciences, 2022, 23, 1667. | 1.8 | 2 |
| 640 | ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 801506. | 1.3 | 16 |
| 641 | Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. OncoImmunology, 2022, 11, . | 2.1 | 2 |
| 642 | Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers, 2022, 14, 621. | 1.7 | 34 |
| 643 | Clinical Significance of the Duality of Wnt/Î²-Catenin Signaling in Human Hepatocellular Carcinoma. Cancers, 2022, 14, 444. | 1.7 | 20 |
| 644 | EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 780509. | 2.2 | 2 |
| 645 | The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?. International Journal of Biological Sciences, 2022, 18, 536-551. | 2.6 | 54 |
| 646 | Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. Journal of Translational Medicine, 2022, 20, 49. | 1.8 | 9 |
| 647 | SHC4 promotes tumor proliferation and metastasis by activating STAT3 signaling in hepatocellular carcinoma. Cancer Cell International, 2022, 22, 24. | 1.8 | 6 |
| 648 | Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Medicine, 2022, 14, 1. | 3.6 | 68 |
| 649 | Spindle and Kinetochore-associated Family Genes are Prognostic and Predictive Biomarkers in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000. | 0.7 | 0 |
| 650 | Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression. Cell Death and Disease, 2022, 13, 79. | 2.7 | 14 |
| 651 | Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to antiâ€“programmed cell death proteinâ€1 therapy. Hepatology, 2022, 76, 1602-1616. | 3.6 | 18 |
| 652 | Upregulation of TMCO3 Promoting Tumor Progression and Contributing to the Poor Prognosis of Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000. | 0.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 653 | SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGFÎ²/PI3K/AKT/GSK3Î²Âpathway. Cancer Cell International, 2022, 22, 1. | 1.8 | 67 |
| 654 | Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. Journal of Personalized Medicine, 2022, 12, 149. | 1.1 | 14 |
| 655 | Role of Exosomes in Immune Microenvironment of Hepatocellular Carcinoma. Journal of Oncology, 2022, 2022, 1-15. | 0.6 | 16 |
| 656 | Cancer Genomic Alterations Can Be Potential Biomarkers Predicting Microvascular Invasion and Early Recurrence of Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 783109. | 1.3 | 3 |
| 657 | The role of RNA binding proteins in hepatocellular carcinoma. Advanced Drug Delivery Reviews, 2022, 182, 114114. | 6.6 | 9 |
| 658 | The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma. Molecular Medicine, 2022, 28, 16. | 1.9 | 37 |
| 659 | Successful conversion therapy and radical resection for huge Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma: A case report. World Chinese Journal of Digestology, 2022, 30, 164-168. | 0.0 | 0 |
| 660 | Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. Journal of Hepatology, 2022, 77, 116-127. | 1.8 | 40 |
| 661 | Mapping oncogenic protein interactions for precision medicine. International Journal of Cancer, 2022, , . | 2.3 | 6 |
| 662 | Remodeling Tumorâ€Associated Neutrophils to Enhance Dendritic Cellâ€Based HCC Neoantigen Nanoâ€Vaccine Efficiency. Advanced Science, 2022, 9, e2105631. | 5.6 | 51 |
| 663 | Multiâ€omics data identified <scp>TP53</scp> and <scp>LRP1B</scp> as key regulatory gene related to immune phenotypes via <scp>EPCAM</scp> in <scp>HCC</scp>. Cancer Medicine, 2022, 11, 2145-2158. | 1.3 | 2 |
| 664 | An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 2046-2058. | 0.6 | 2 |
| 665 | AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review. Liver Cancer, 2022, 11, 94-112. | 4.2 | 10 |
| 666 | Serum gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can predict the prognosis of hepatocellular carcinoma: a meta-analysis and systematic review. Translational Cancer Research, 2022, 11, 745-753. | 0.4 | 5 |
| 667 | Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. Advances in Cancer Research, 2022, , 319-341. | 1.9 | 2 |
| 668 | A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response. Mathematical Biosciences and Engineering, 2022, 19, 4719-4736. | 1.0 | 1 |
| 669 | LncRNA PCED1B-AS1 Upregulation in Hepatocellular Carcinoma and Regulation of the miR-10a/BCL6 Axis to Promote Cell Proliferation. Critical Reviews in Eukaryotic Gene Expression, 2022, 32, 11-20. | 0.4 | 2 |
| 671 | The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death and Disease, 2022, 13, 146. | 2.7 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 672 | The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model. BMC Cancer, 2022, 22, 185. | 1.1 | 0 |
| 673 | Comprehensive Analysis of HOX Family Members as Novel Diagnostic and Prognostic Markers for Hepatocellular Carcinoma. Journal of Oncology, 2022, 2022, 1-17. | 0.6 | 4 |
| 674 | CircRNA_0008194 functions as a ceRNA to promote invasion of hepatocellular carcinoma via inhibiting miRâ€190a/AHNAK signaling pathway. Journal of Clinical Laboratory Analysis, 2022, 36, e24286. | 0.9 | 10 |
| 675 | The Role of COL22A1 in the Pathophysiology of Hepatocellular Carcinoma: Evidence from Bioinformatics Exploration. Cancer Management and Research, 0, Volume 14, 739-750. | 0.9 | 0 |
| 676 | The Bright and the Dark Side of TGF-Î² Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. Cancers, 2022, 14, 940. | 1.7 | 16 |
| 677 | Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway. Frontiers in Oncology, 2022, 12, 836333. | 1.3 | 1 |
| 678 | OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression. Cancer Immunology, Immunotherapy, 2022, 71, 2677-2689. | 2.0 | 7 |
| 679 | Drug delivery strategy in hepatocellular carcinoma therapy. Cell Communication and Signaling, 2022, 20, 26. | 2.7 | 21 |
| 680 | Observation on the effect and effective rate of contrast-enhanced ultrasonography in interventional therapy for primary hepatocellular carcinoma. Minerva Gastroenterology, 2022, , . | 0.3 | 0 |
| 681 | Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 813275. | 1.3 | 1 |
| 682 | Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma. JCO Precision Oncology, 2022, 6, e2100335. | 1.5 | 9 |
| 683 | The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma. Frontiers in Immunology, 2022, 13, 861525. | 2.2 | 11 |
| 684 | Integrated Analysis Highlights the Immunosuppressive Role of TREM2+ Macrophages in Hepatocellular Carcinoma. Frontiers in Immunology, 2022, 13, 848367. | 2.2 | 28 |
| 685 | Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. Hepatology International, 2022, 16, 412-422. | 1.9 | 2 |
| 686 | Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. , 2022, 136, 212761. | | 10 |
| 687 | Pyroptosis-Related LncRNA Signature Predicts Prognosis and Is Associated With Immune Infiltration in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 794034. | 1.3 | 12 |
| 688 | Advances in artificial intelligence techniques drive the application of radiomics in the clinical research of hepatocellular carcinoma. , 2022, 1, 49-54. | | 1 |
| 690 | A Novel Gene Signature Based on CDC20 and FCN3 for Prediction of Prognosis and Immune Features in Patients with Hepatocellular Carcinoma. Journal of Immunology Research, 2022, 2022, 1-15. | 0.9 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 691 | Exploration of a Novel Prognostic Nomogram and Diagnostic Biomarkers Based on the Activity Variations of Hallmark Gene Sets in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 830362. | 1.3 | 2 |
| 692 | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers, 2022, 14, 1747. | 1.7 | 36 |
| 693 | Medicaid expansion is associated with a higher likelihood of early diagnosis, resection, transplantation, and overall survival in patients with hepatocellular carcinoma. Hpb, 2022, 24, 1482-1491. | 0.1 | 11 |
| 694 | The clinical relevance of epithelialâ€mesenchymal transition and its correlations with tumorigenic immune infiltrates in hepatocellular carcinoma. Immunology, 2022, 166, 185-196. | 2.0 | 6 |
| 695 | Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2449-2460. | 3.2 | 39 |
| 696 | Hepatocellular carcinomaâ€infiltrating Î³Î´ T cells are functionally defected and allogenic Vδ2<sup>+</sup> Î³Î´ T cell can be a promising complement. Clinical and Translational Medicine, 2022, 12, e800. | 1.7 | 13 |
| 697 | PRC1 and RACGAP1 are Diagnostic Biomarkers of Early HCC and PRC1 Drives Self-Renewal of Liver Cancer Stem Cells. Frontiers in Cell and Developmental Biology, 2022, 10, 864051. | 1.8 | 6 |
| 698 | CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway. Science China Life Sciences, 2022, 65, 1998-2016. | 2.3 | 9 |
| 699 | Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101853. | 0.7 | 6 |
| 700 | Sarcopenia and Systemic Inflammation Response Index Predict Response to Systemic Therapy for Hepatocellular Carcinoma and Are Associated With Immune Cells. Frontiers in Oncology, 2022, 12, 854096. | 1.3 | 13 |
| 701 | Association of the MARCO polymorphism rs6761637 with hepatocellular carcinoma susceptibility and clinical characteristics. Immunologic Research, 2022, , 1. | 1.3 | 2 |
| 702 | Targeting tumor associated macrophages in hepatocellular carcinoma. Biochemical Pharmacology, 2022, 199, 114990. | 2.0 | 13 |
| 703 | Low expression of moonlight gene ALAD is correlated with poor prognosis in hepatocellular carcinoma. Gene, 2022, 825, 146437. | 1.0 | 5 |
| 704 | Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma. Cancer Letters, 2022, 536, 215642. | 3.2 | 9 |
| 705 | An RNAâ€“RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity. Signal Transduction and Targeted Therapy, 2021, 6, 421. | 7.1 | 48 |
| 706 | Identification of Therapeutic Targets and Prognostic Biomarkers Among Chemokine (C-C Motif) Ligands in the Liver Hepatocellular Carcinoma Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 748269. | 1.8 | 5 |
| 707 | FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opinion on Investigational Drugs, 2022, 31, 393-400. | 1.9 | 4 |
| 708 | Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with isoâ€high intensity in theÂhepatobiliary phase of Gdâ€EOBâ€DTPAâ€MRI. Molecular and Clinical Oncology, 2021, 16, 53. | 0.4 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 709 | Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdominal Radiology, 2022, 47, 969-980. | 1.0 | 11 |
| 710 | Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma. Cancer Cell International, 2021, 21, 669. | 1.8 | 20 |
| 711 | An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 766609. | 1.6 | 9 |
| 712 | Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 8302-8322. | 1.4 | 12 |
| 713 | Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. Frontiers in Oncology, 2021, 11, 803133. | 1.3 | 83 |
| 714 | Downregulated Expression of miRNA-130a-5p Aggravates Hepatoma Progression via Targeting PTP4A2. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-12. | 0.7 | 2 |
| 715 | Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities. Cancers, 2022, 14, 48. | 1.7 | 30 |
| 716 | Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression. BioMed Research International, 2021, 2021, 1-14. | 0.9 | 3 |
| 717 | Hypoxia responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy. Drug Delivery, 2022, 29, 138-148. | 2.5 | 42 |
| 718 | Construction and Validation of a Combined Ferroptosis and Hypoxia Prognostic Signature for Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 809672. | 1.6 | 12 |
| 719 | Ðembrolizumab as second line therapy for hepatocellular patient. Meditsinskiy Sovet, 2021, , 150-154. | 0.1 | 0 |
| 720 | Nonhepatic Cancer in the Pediatric Liver Transplant Population: Guidelines From the ILTS-SETH Consensus Conference. Transplantation, 2022, 106, e46-e51. | 0.5 | 2 |
| 721 | RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding. Cell Death and Disease, 2022, 13, 6. | 2.7 | 10 |
| 722 | The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents. Frontiers in Oncology, 2021, 11, 804412. | 1.3 | 4 |
| 723 | Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 793343. | 2.2 | 21 |
| 724 | Delta-tocotrienol enhances the anti-tumor effects of interferon alpha through reactive oxygen species and Erk/MAPK signaling pathways in hepatocellular carcinoma cells. Canadian Journal of Physiology and Pharmacology, 2021, , 1-11. | 0.7 | 1 |
| 725 | hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miRâ€139â€3p/CCL5 axis. Cancer Science, 2022, 113, 634-647. | 1.7 | 26 |
| 726 | MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 113-126. | 1.8 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 727 | CpG Site-Specific Methylation-Modulated Divergent Expression of PRSS3 Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 831268. | 1.3 | 2 |
| 728 | Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma. BMC Cancer, 2022, 22, 431. | 1.1 | 23 |
| 729 | HDACs and the epigenetic plasticity of cancer cells: Target the complexity. , 2022, 238, 108190. | | 14 |
| 730 | Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. Expert Review of Gastroenterology and Hepatology, 2022, 16, 333-339. | 1.4 | 65 |
| 731 | MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases. Cancers, 2022, 14, 1994. | 1.7 | 3 |
| 732 | Development an Immune-Related MicroRNA Risk Index in Hepatocellular Carcinoma. Journal of Oncology, 2022, 2022, 1-13. | 0.6 | 0 |
| 733 | Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO Reports, 2022, , e54275. | 2.0 | 5 |
| 734 | Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer. European Journal of Medicinal Chemistry, 2022, 237, 114376. | 2.6 | 3 |
| 735 | Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research, 2022, 28, 2297-2305. | 3.2 | 8 |
| 736 | Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/Î²-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma. Cancers, 2022, 14, 2066. | 1.7 | 8 |
| 737 | An immune subtype-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing analysis. Aging, 2022, 14, 3276-3292. | 1.4 | 34 |
| 738 | Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Biology, 2022, 11, 585. | 1.3 | 5 |
| 767 | The combined signatures of hypoxia and cellular landscape provides a prognostic and therapeutic biomarker in hepatitis B virusâ€related hepatocellular carcinoma. International Journal of Cancer, 2022, 151, 809-824. | 2.3 | 11 |
| 768 | A simple 2-parameter blood test alert for the presence of small hepatocellular carcinomas.. Clinical Practice (London, England), 2021, 18, 1804-1809. | 0.1 | 0 |
| 769 | Decoding the functional role of extracellular vesicles in hepatocellular carcinoma: implications in clinical theranostics. , 2022, , 301-339. | | 0 |
| 770 | Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 844013. | 1.8 | 0 |
| 772 | Serum Amino Acid Profiles Predict the Development of Hepatocellular Carcinoma in Patients with Chronic HBV Infection. ACS Omega, 2022, 7, 15795-15808. | 1.6 | 7 |
| 773 | Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy. Frontiers in Microbiology, 2022, 13, 873160. | 1.5 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 774 | Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidinyl/Cationic Lipid against Hepatocellular Carcinoma. Molecular Pharmaceutics, 2022, 19, 4552-4564. | 2.3 | 6 |
| 775 | EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway. Journal of Experimental and Clinical Cancer Research, 2022, 41, 164. | 3.5 | 24 |
| 776 | Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. Cancers, 2022, 14, 2381. | 1.7 | 4 |
| 777 | Omega-3 Polyunsaturated Fatty Acids Provoke Apoptosis in Hepatocellular Carcinoma through Knocking Down the STAT3 Activated Signaling Pathway: In Vivo and In Vitro Study. Molecules, 2022, 27, 3032. | 1.7 | 2 |
| 778 | PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers, 2022, 2022, 1-18. | 0.6 | 1 |
| 779 | Foreword. Clinical Drug Investigation, 2022, , . | 1.1 | 0 |
| 780 | Dysregulation of immune checkpoint proteins in hepatocellular carcinoma: Impact on metabolic reprogramming. Current Opinion in Pharmacology, 2022, 64, 102232. | 1.7 | 1 |
| 781 | Necroptosis modulation by cisplatin and sunitinib in hepatocellular carcinoma cell line. Life Sciences, 2022, 301, 120594. | 2.0 | 2 |
| 782 | Construction and validation of a pyroptosis-related gene signature in hepatocellular carcinoma based on RNA sequencing. Translational Cancer Research, 2021, . | 0.4 | 1 |
| 783 | Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401. | 5.7 | 126 |
| 784 | Identification of Context-Specific Fitness Genes Associated With Metabolic Rearrangements for Prognosis and Potential Treatment Targets for Liver Cancer. Frontiers in Genetics, 2022, 13, . | 1.1 | 1 |
| 785 | A novel hypoxia-driven gene signature that can predict the prognosis of hepatocellular carcinoma. Bioengineered, 2022, 13, 12193-12210. | 1.4 | 6 |
| 786 | DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis. Biochemical Pharmacology, 2022, 201, 115093. | 2.0 | 4 |
| 787 | Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. Expert Review of Precision Medicine and Drug Development, 2022, 7, 50-57. | 0.4 | 1 |
| 788 | AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis. Cell Death and Disease, 2022, 13, 469. | 2.7 | 3 |
| 789 | Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience. Journal of Cancer, 2022, 13, 2656-2661. | 1.2 | 6 |
| 790 | Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. Computational Intelligence and Neuroscience, 2022, 2022, 1-14. | 1.1 | 1 |
| 791 | Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/Î²â€catenin signal activation. Oncology Letters, 2022, 24, . | 0.8 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 793 | Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. International Journal of Clinical Oncology, 0, , . | 1.0 | 2 |
| 794 | Integrative Analysis Identifies Cell-Type-Specific Genes Within Tumor Microenvironment as Prognostic Indicators in Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 795 | Comprehensive Analysis of a Cancer-Immunity Cycleâ€“Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer. Frontiers in Immunology, 0, 13, . | 2.2 | 10 |
| 796 | Long nonâ€coding RNAs in virusâ€related cancers. Reviews in Medical Virology, 2022, 32, . | 3.9 | 5 |
| 797 | RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open, 2022, 12, e052294. | 0.8 | 5 |
| 798 | Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. Frontiers in Oncology, 0, 12, . | 1.3 | 5 |
| 799 | NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17. | 1.9 | 4 |
| 801 | The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications. Frontiers in Immunology, 0, 13, . | 2.2 | 20 |
| 802 | Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. Journal of Immunology Research, 2022, 2022, 1-21. | 0.9 | 6 |
| 804 | Tissue factor promotes HCC carcinogenesis by inhibiting BCL2-dependent autophagy. Bulletin Du Cancer, 2022, , . | 0.6 | 2 |
| 805 | Imaging for better responses to immunotherapy in hepatocellular carcinoma. Hepatology, 2023, 77, 6-9. | 3.6 | 1 |
| 807 | Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302. Liver Cancer, 2022, 11, 440-450. | 4.2 | 22 |
| 808 | A Multifunctional Vanadium-Iron-Oxide Nanoparticle Eradicates Hepatocellular Carcinoma via Targeting Tumor and Endothelial Cells. ACS Applied Materials & Interfaces, 2022, 14, 28514-28526. | 4.0 | 12 |
| 809 | Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs. Frontiers in Pharmacology, 0, 13, . | 1.6 | 3 |
| 810 | Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma. Meditsinskiy Sovet, 2022, , 157-162. | 0.1 | 0 |
| 811 | circACTG1 Promotes Hepatocellular Carcinoma Progression by Regulating miR-940/RIF1 Axis and Activating AKT/mTOR Pathway. Journal of Immunology Research, 2022, 2022, 1-13. | 0.9 | 2 |
| 812 | L-Selenocysteine induced HepG-2 cells apoptosis through reactive oxygen species-mediated signaling pathway. Molecular Biology Reports, 2022, 49, 8381-8390. | 1.0 | 4 |
| 813 | The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF-Î²B Signaling. Medicina (Lithuania), 2022, 58, 798. | 0.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 814 | Methyltransferase 1 is required for nonhomologous endâ€joining repair and renders hepatocellular carcinoma resistant to radiotherapy. Hepatology, 2023, 77, 1896-1910. | 3.6 | 17 |
| 816 | Iron Oxide Nanoparticles Functionalized with Fucoidan: a Potential Theranostic Nanotool for Hepatocellular Carcinoma. ChemBioChem, 2022, 23, . | 1.3 | 1 |
| 817 | 3D printed hydrogel scaffolds combining glutathione depletion-induced ferroptosis and photothermia-augmented chemodynamic therapy for efficiently inhibiting postoperative tumor recurrence. Journal of Nanobiotechnology, 2022, 20, . | 4.2 | 25 |
| 818 | Ligand-modified Nanomaterials for Specific Targeting of Hepatocellular Carcinoma. , 2022, 2, . | | 0 |
| 819 | Down-regulation of circPTTG1IP induces hepatocellular carcinoma development via miR-16-5p/RNF125/JAK1 axis. Cancer Letters, 2022, 543, 215778. | 3.2 | 12 |
| 820 | Clinical significance and immunogenomic landscape analysis of glycolysis-associated prognostic model to guide clinical therapy in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2022, 13, 1351-1366. | 0.6 | 1 |
| 821 | Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer. Frontiers in Genetics, 0, 13, . | 1.1 | 1 |
| 823 | HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters. International Journal of Genomics, 2022, 2022, 1-12. | 0.8 | 3 |
| 824 | Fusobacterium nucleatum and Malignant Tumors of the Digestive Tract: A Mechanistic Overview. Bioengineering, 2022, 9, 285. | 1.6 | 2 |
| 825 | Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours. Frontiers in Pharmacology, 0, 13, . | 1.6 | 3 |
| 826 | miR-200a-3p- and miR-181-5p-Mediated HOXB5 Upregulation Promotes HCC Progression by Transcriptional Activation of EGFR. Frontiers in Oncology, 0, 12, . | 1.3 | 4 |
| 827 | Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 0, 9, . | 1.6 | 6 |
| 828 | Multiomics technologies: role in disease biomarker discoveries and therapeutics. Briefings in Functional Genomics, 2023, 22, 76-96. | 1.3 | 5 |
| 829 | A miR-9-5p/FOXO1/CPEB3 Feed-Forward Loop Drives the Progression of Hepatocellular Carcinoma. Cells, 2022, 11, 2116. | 1.8 | 4 |
| 830 | Development and Verification of a Combined Immune- and Metabolism-Related Prognostic Signature for Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 0 |
| 831 | Suppressive Effects of Siegesbeckia orientalis Ethanolic Extract on Proliferation and Migration of Hepatocellular Carcinoma Cells through Promoting Oxidative Stress, Apoptosis and Inflammatory Responses. Pharmaceuticals, 2022, 15, 826. | 1.7 | 1 |
| 832 | A Novel Necroptosis-Related Gene Signature in Skin Cutaneous Melanoma Prognosis and Tumor Microenvironment. Frontiers in Genetics, 0, 13, . | 1.1 | 14 |
| 833 | Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 0, 9, . | 1.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 834 | Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma. Cell Death and Disease, 2022, 13, . | 2.7 | 13 |
| 835 | Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway. Acta Biochimica Et Biophysica Sinica, 2022, 54, 974-986. | 0.9 | 7 |
| 836 | Identification of chromosomal instability-associated genes as hepatocellular carcinoma progression-related biomarkers to guide clinical diagnosis, prognosis and therapy. Computers in Biology and Medicine, 2022, 148, 105896. | 3.9 | 4 |
| 837 | Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, . | 1.3 | 3 |
| 838 | Seco-Lupane Triterpene Derivatives Induce Ferroptosis through GPX4/ACSL4 Axis and Target Cyclin D1 to Block the Cell Cycle. Journal of Medicinal Chemistry, 2022, 65, 10014-10044. | 2.9 | 6 |
| 839 | miR-6071 inhibits hepatocellular carcinoma progression via targeting PTPN11. Archives of Biochemistry and Biophysics, 2022, 727, 109345. | 1.4 | 1 |
| 840 | Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling via Interaction With FLNA. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 841 | LINC01419 Promotes the Proliferation of Hepatoma Cells by Recruiting XRCC5 and Regulating Its Phosphorylation to Repair DNA Damage. Disease Markers, 2022, 2022, 1-10. | 0.6 | 2 |
| 842 | Comprehensive Analysis of Prognostic Value and Immune Infiltration of Ficolin Family Members in Hepatocellular Carcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 2 |
| 843 | Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 7971. | 1.8 | 3 |
| 844 | Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 3 |
| 845 | CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 14 |
| 846 | Systematic Analysis of Long Non-Coding RNA Genes in Nonalcoholic Fatty Liver Disease. Non-coding RNA, 2022, 8, 56. | 1.3 | 7 |
| 847 | Long nonâ€‘coding RNA PART1: dual role in cancer. Human Cell, 2022, 35, 1364-1374. | 1.2 | 6 |
| 848 | FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition. International Journal of Molecular Sciences, 2022, 23, 8305. | 1.8 | 6 |
| 849 | Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma. Chinese Medicine, 2022, 17, . | 1.6 | 10 |
| 850 | Prognostic value of exosomal noncoding RNA in hepatocellular carcinoma: a meta-analysis. Carcinogenesis, 2022, 43, 754-765. | 1.3 | 2 |
| 851 | Indocyanine green fluorescence-guided laparoscopic hepatectomy versus conventional laparoscopic hepatectomy for hepatocellular carcinoma: A single-center propensity score matching study. Frontiers in Oncology, 0, 12, . | 1.3 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 852 | Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2022, 12, 139-150. | 0.1 | 2 |
| 853 | Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy. Cancer Immunology, Immunotherapy, 0, , . | 2.0 | 3 |
| 854 | Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis. Frontiers in Genetics, 0, 13, . | 1.1 | 11 |
| 855 | Monocarboxylate transporter upregulation in induced regulatory T cells promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma patients. Frontiers in Oncology, 0, 12, . | 1.3 | 3 |
| 856 | Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 6 |
| 857 | The E3 ubiquitin ligase MG53 inhibits hepatocellular carcinoma by targeting RAC1 signaling. Oncogenesis, 2022, 11, . | 2.1 | 12 |
| 858 | miR-3154 promotes hepatocellular carcinoma progression via suppressing HNF4Î±. Carcinogenesis, 2022, 43, 1002-1014. | 1.3 | 6 |
| 859 | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 14 |
| 860 | NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma. BMC Gastroenterology, 2022, 22, . | 0.8 | 3 |
| 861 | KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma. Anti-Cancer Drugs, 2022, 33, 840-849. | 0.7 | 8 |
| 863 | Characterization of coagulation-related gene signature to predict prognosis and tumor immune microenvironment in skin cutaneous melanoma. Frontiers in Oncology, 0, 12, . | 1.3 | 20 |
| 864 | Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, . | 1.3 | 7 |
| 865 | Comprehensive analysis of complement-associated molecular features in hepatocellular carcinoma. Acta Biochimica Et Biophysica Sinica, 2022, , . | 0.9 | 0 |
| 866 | <scp>DLK1</scp>â€directed chimeric antigen receptor Tâ€cell therapy for hepatocellular carcinoma. Liver International, 2022, 42, 2524-2537. | 1.9 | 4 |
| 867 | A Comprehensive Evaluation of Prognostic Value and Immune Infiltration of KDM1 Family in Hepatocellular Carcinoma. Advances in Therapy, 0, , . | 1.3 | 0 |
| 868 | Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy. , 2022, 39, . | | 1 |
| 870 | The prognostic significance of inflammation-immunity-nutrition score on postoperative survival and recurrence in hepatocellular carcinoma patients. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 871 | A Cell Differentiation Trajectory-Related Signature for Predicting the Prognosis of Lung Adenocarcinoma. Genetical Research, 2022, 2022, 1-11. | 0.3 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 872 | Up-Regulation of RACGAP1 Promotes Progressions of Hepatocellular Carcinoma Regulated by GABPA via PI3K/AKT Pathway. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-16. | 1.9 | 6 |
| 873 | Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Scientific Reports, 2022, 12, . | 1.6 | 6 |
| 874 | Prognostic and Immunological Significance of FUNDC1 in Hepatocellular Carcinoma: A Study on TCGA Mining. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-15. | 0.7 | 3 |
| 875 | microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway. Cell Cycle, 2022, 21, 2651-2663. | 1.3 | 3 |
| 877 | EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma. Cell Discovery, 2022, 8, . | 3.1 | 1 |
| 878 | The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology, 2023, 77, 1773-1796. | 3.6 | 101 |
| 879 | Multi-omics analysis revealed the role of extracellular vesicles in hepatobiliary & pancreatic tumor. Journal of Controlled Release, 2022, 350, 11-25. | 4.8 | 3 |
| 880 | The pattern of expression and prognostic value of key regulators for m7G RNA methylation in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 6 |
| 881 | Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. International Journal of Molecular Sciences, 2022, 23, 10038. | 1.8 | 4 |
| 882 | A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 20 |
| 883 | pH-activated nanoplatform for visualized photodynamic and ferroptosis synergistic therapy of tumors. Journal of Controlled Release, 2022, 350, 525-537. | 4.8 | 18 |
| 884 | Wnt/Î²-catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: A review. Biomedicine and Pharmacotherapy, 2022, 155, 113713. | 2.5 | 5 |
| 885 | Identification of Subtypes of HCC Using Bioinformatics and the Hepatocyte Differentiation Model. Methods in Molecular Biology, 2022, , 253-258. | 0.4 | 0 |
| 886 | Construction and Evaluation of GPC3-Targeted Immunotoxins as a Novel Therapeutic Modality for Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 887 | Efficacy of Radiofrequency Ablation Following Transarterial Chemoembolization Combined with Sorafenib for Intermediate Stage Recurrent Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 888 | Identification of a novel histone phosphorylation prognostic signature in hepatocellular carcinoma based on bulk and single-cell RNA sequencing. Frontiers in Endocrinology, 0, 13, . | 1.5 | 3 |
| 889 | Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients. Journal of Gastrointestinal Oncology, 2022, 13, 1898-1906. | 0.6 | 3 |
| 890 | E2F1 as a potential prognostic and therapeutic biomarker by affecting tumor development and immune microenvironment in hepatocellular carcinoma. Translational Cancer Research, 2022, 11, 2713-2732. | 0.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 891 | Farnesiferol C Exerts Antiproliferative Effects on Hepatocellular Carcinoma HepG2 Cells by Instigating ROS-Dependent Apoptotic Pathway. Pharmaceuticals, 2022, 15, 1070. | 1.7 | 5 |
| 892 | Predicting prognosis and immune responses in hepatocellular carcinoma based on N7-methylguanosine-related long noncoding RNAs. Frontiers in Genetics, 0, 13, . | 1.1 | 0 |
| 893 | Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy. Frontiers in Immunology, 0, 13, . | 2.2 | 3 |
| 894 | TRIM36 inhibits tumorigenesis through the Wnt/Î²-catenin pathway and promotes caspase-dependent apoptosis in hepatocellular carcinoma. Cancer Cell International, 2022, 22, . | 1.8 | 2 |
| 895 | Combination of Peglated-H1/HGFK1 Nanoparticles and TAE in the Treatment of Hepatocellular Carcinoma. Applied Biochemistry and Biotechnology, 2023, 195, 505-518. | 1.4 | 4 |
| 896 | Sorafenib-Loaded Cu2â^'xSe Nanoparticles Boost Photothermalâ€“Synergistic Targeted Therapy against Hepatocellular Carcinoma. Nanomaterials, 2022, 12, 3191. | 1.9 | 6 |
| 897 | <scp>PSMB5</scp> overexpression is correlated with tumor proliferation and poor prognosis in hepatocellular carcinoma. FEBS Open Bio, 2022, 12, 2025-2041. | 1.0 | 7 |
| 898 | Identification of the hub and prognostic genes in liver hepatocellular carcinoma via bioinformatics analysis. Frontiers in Molecular Biosciences, 0, 9, . | 1.6 | 4 |
| 899 | Comprehensive Molecular Analysis Identified an SRSF Family-Based Score for Prognosis and Therapy Efficiency Prediction in Hepatocellular Carcinoma. Cancers, 2022, 14, 4727. | 1.7 | 0 |
| 900 | Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3â€“ABCB1 Signaling in Hepatocellular Carcinoma. Cancer Research, 2022, 82, 3845-3857. | 0.4 | 26 |
| 901 | Integrated System Pharmacology Approaches to Elucidate Multi-Target Mechanism of Solanum surattense against Hepatocellular Carcinoma. Molecules, 2022, 27, 6220. | 1.7 | 5 |
| 902 | Synergizing liver systemic treatments with interventional oncology: friend or foe?. British Journal of Radiology, 2022, 95, . | 1.0 | 1 |
| 903 | Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 5 |
| 904 | Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Frontiers in Oncology, 0, 12, . | 1.3 | 9 |
| 905 | A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients. Current Oncology, 2022, 29, 6992-7011. | 0.9 | 2 |
| 906 | Prognostic Implication of a Cuproptosis-Related miRNA Signature in Hepatocellular Carcinoma. Journal of Healthcare Engineering, 2022, 2022, 1-14. | 1.1 | 6 |
| 907 | METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma. Human Cell, 2022, 35, 1838-1855. | 1.2 | 10 |
| 908 | Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma. Clinical and Experimental Medicine, 2023, 23, 2065-2083. | 1.9 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 909 | All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma. Biomedicines, 2022, 10, 2351. | 1.4 | 1 |
| 910 | Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy. Frontiers in Immunology, 0, 13, . | 2.2 | 4 |
| 911 | Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open, 2022, 6, . | 0.7 | 20 |
| 912 | Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma. BMC Gastroenterology, 2022, 22, . | 0.8 | 3 |
| 913 | NSUN2-Mediated mRNA m5C Modification Regulates the Progression of Hepatocellular Carcinoma. Genomics, Proteomics and Bioinformatics, 2023, 21, 823-833. | 3.0 | 4 |
| 914 | HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET. Journal of Experimental and Clinical Cancer Research, 2022, 41, . | 3.5 | 11 |
| 916 | Molecular Classification of Hepatocellular Carcinoma Using Wntâ€“Hippo Signaling Pathway-Related Genes. Cancers, 2022, 14, 4580. | 1.7 | 3 |
| 917 | Eupalinolide A induces autophagy via the ROS/ERK signaling pathway in hepatocellular carcinoma cells inÂvitro and inÂvivo. International Journal of Oncology, 2022, 61, . | 1.4 | 3 |
| 918 | Berberine enhances the anti-hepatocellular carcinoma effect of NK92-MI cells through inhibiting IFN-gamma-mediated PD-L1 expression. Liver Research, 2022, 6, 167-174. | 0.5 | 0 |
| 919 | Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy. Cancers, 2022, 14, 4647. | 1.7 | 1 |
| 920 | Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatocellular carcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 0 |
| 921 | Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting Î²-catenin mutation in patients with hepatocellular carcinoma: A retrospective study. Frontiers in Oncology, 0, 12, . | 1.3 | 2 |
| 922 | Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Frontiers in Immunology, 0, 13, . | 2.2 | 8 |
| 923 | Popular deep learning algorithms for disease prediction: a review. Cluster Computing, 2023, 26, 1231-1251. | 3.5 | 18 |
| 924 | Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers, 2022, 14, 4616. | 1.7 | 18 |
| 925 | The Systematic Analyses of RING Finger Gene Signature for Predicting the Prognosis of Patients with Hepatocellular Carcinoma. Journal of Oncology, 2022, 2022, 1-17. | 0.6 | 6 |
| 926 | Multitargeting Strategy Using Tetrathiomolybdate and Lenvatinib: Maximizing Antiangiogenesis Activity in a Preclinical Liver Cancer Model. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 786-793. | 0.9 | 5 |
| 927 | Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. World Journal of Gastrointestinal Oncology, 2022, 14, 1622-1636. | 0.8 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 928 | Clinical neutrophil-associated genes as reliable predictors of hepatocellular carcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 1 |
| 929 | Identification of copper metabolism and cuproptosis-related subtypes for predicting prognosis tumor microenvironment and drug candidates in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 4 |
| 930 | Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 4 |
| 931 | Activation of Piezo1 contributes to matrix stiffnessâ€induced angiogenesis in hepatocellular carcinoma. Cancer Communications, 2022, 42, 1162-1184. | 3.7 | 27 |
| 932 | Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma. BMC Cancer, 2022, 22, . | 1.1 | 4 |
| 933 | Emergent impact of lifestyle on tumor progression and response to therapy. International Review of Cell and Molecular Biology, 2022, , ix-xvii. | 1.6 | 0 |
| 934 | Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Advances, 2022, 12, 31068-31082. | 1.7 | 8 |
| 935 | The Complement System: A Potential Therapeutic Target in Liver Cancer. Life, 2022, 12, 1532. | 1.1 | 1 |
| 936 | Hepatocellular Carcinoma Medical Therapy. Updates in Surgery Series, 2023, , 173-179. | 0.0 | 0 |
| 937 | Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1109-1125. | 1.8 | 11 |
| 938 | Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Pharmaceutics, 2022, 14, 2263. | 2.0 | 3 |
| 939 | Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence. Hpb, 2023, 25, 218-228. | 0.1 | 3 |
| 940 | Hepatocellular carcinoma mutation landscape and its differences between Asians and Whites. Hepatobiliary Surgery and Nutrition, 2022, 11, 724-728. | 0.7 | 1 |
| 941 | MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling. Cell Death Discovery, 2022, 8, . | 2.0 | 13 |
| 942 | Targeting drugs to tumours using cell membrane-coated nanoparticles. Nature Reviews Clinical Oncology, 2023, 20, 33-48. | 12.5 | 176 |
| 943 | A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma. Frontiers in Oncology, 0, 12, . | 1.3 | 7 |
| 944 | Long noncoding RNA HULC regulates the NFâ€ºB pathway and represents a promising prognostic biomarker in liver cancer. Cancer Medicine, 2023, 12, 5124-5136. | 1.3 | 3 |
| 946 | Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response. Cancers, 2022, 14, 4850. | 1.7 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 948 | Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, . | 3.1 | 25 |
| 950 | Genomeâ€Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment. Advanced Science, 2022, 9, . | 5.6 | 7 |
| 951 | Acteoside (Verbascoside): A prospective therapeutic alternative against Hepatocellular Carcinoma by inhibiting the expression of AXL, FGFR, BRAF, TIE2 and RAF1 targets. Combinatorial Chemistry and High Throughput Screening, 2022, 26, . | 0.6 | 1 |
| 952 | Identification of lipid metabolism-associated genes as prognostic biomarkers based on the immune microenvironment in hepatocellular carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, . | 1.8 | 4 |
| 953 | The Prognostic Significance of FKBP1A and Its Related Immune Infiltration in Liver Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 12797. | 1.8 | 1 |
| 954 | Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma. BMC Gastroenterology, 2022, 22, . | 0.8 | 0 |
| 955 | NPRL2 downâ€regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression. Hepatology Communications, 2022, 6, 3563-3577. | 2.0 | 3 |
| 956 | Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77. European Journal of Medicinal Chemistry, 2022, 244, 114849. | 2.6 | 4 |
| 957 | Chemokine CCL5 immune subtypes of human liver cancer with prognostic significance. International Immunopharmacology, 2022, 113, 109372. | 1.7 | 3 |
| 958 | Alcohol dehydrogenase 4 is a TP53â€‘associated gene signature for the prediction of prognosis in hepatocellular carcinoma. Oncology Letters, 2022, 25, . | 0.8 | 4 |
| 959 | Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 203-222. | 8.2 | 113 |
| 961 | Have We Found the â€œHoly Grailâ€•That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?. Gastroenterology, 2023, 164, 15-18. | 0.6 | 0 |
| 962 | Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 964 | Integrative multiomics evaluation reveals the importance of pseudouridine synthases in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 12 |
| 965 | Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World Journal of Gastroenterology, 0, 28, 6034-6044. | 1.4 | 6 |
| 966 | LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia. Scientific Reports, 2022, 12, . | 1.6 | 2 |
| 967 | Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma. International Immunopharmacology, 2022, 113, 109411. | 1.7 | 0 |
| 968 | Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma. International Immunopharmacology, 2022, 113, 109393. | 1.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 969 | The roles of lncRNA functions and regulatory mechanisms in the diagnosis and treatment of hepatocellular carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, . | 1.8 | 4 |
| 970 | Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncology, 2022, 18, 3769-3782. | 1.1 | 11 |
| 971 | Mallotucin D, a Clerodane Diterpenoid from Croton crassifolius, Suppresses HepG2 Cell Growth via Inducing Autophagic Cell Death and Pyroptosis. International Journal of Molecular Sciences, 2022, 23, 14217. | 1.8 | 7 |
| 972 | Integrated analysis of transcriptomics and metabolomics in human hepatocellular carcinoma HepG2215 cells after YAP1 knockdown. Acta Histochemica, 2023, 125, 151987. | 0.9 | 2 |
| 973 | Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma. Computers in Biology and Medicine, 2023, 152, 106348. | 3.9 | 1 |
| 974 | Research progress on the role of cholesterol in hepatocellular carcinoma. European Journal of Pharmacology, 2023, 938, 175410. | 1.7 | 4 |
| 975 | Galactose engineered nanocarriers: Hopes and hypes in cancer therapy. European Polymer Journal, 2023, 183, 111759. | 2.6 | 17 |
| 976 | Knockdown of PKMYT1 is associated with autophagy inhibition and apoptosis induction and suppresses tumor progression in hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2023, 640, 173-182. | 1.0 | 3 |
| 977 | First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211406. | 1.4 | 5 |
| 978 | Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis. Expert Opinion on Drug Safety, 2023, 22, 323-329. | 1.0 | 0 |
| 979 | Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut, 2023, 72, 1568-1580. | 6.1 | 6 |
| 980 | Canonical WNT Signaling Activated by WNT7B Contributes to L-HBs-Mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting Mitophagy. Cancers, 2022, 14, 5781. | 1.7 | 5 |
| 981 | Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. Expert Opinion on Investigational Drugs, 2022, 31, 1151-1167. | 1.9 | 3 |
| 982 | Clinical value of identifying genes that inhibit hepatocellular carcinomas. Expert Review of Molecular Diagnostics, 2022, 22, 1009-1035. | 1.5 | 1 |
| 983 | An Elevated Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Liver Cancer after Interventional Treatments. BioMed Research International, 2022, 2022, 1-8. | 0.9 | 3 |
| 984 | Combining Î³â€GT, PIVKAâ€II, and AFP to Predict Longâ€Term Prognosis in Patients with Hepatocellular Carcinoma after Hepatectomy. Clinical and Experimental Pharmacology and Physiology, 0, , . | 0.9 | 0 |
| 985 | Construction of a m5C-related long non-coding RNA signature for the prognosis of hepatocellular carcinoma. Human Cell, 2023, 36, 712-724. | 1.2 | 3 |
| 986 | Transarterial chemoembolisation plus I125 seeds implantation for people with unresectable hepatocellular carcinoma. The Cochrane Library, 2022, 2022, . | 1.5 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 987 | Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , . | 1.2 | 0 |
| 988 | Hsa_circ_0006988 Promotes Sorafenib Resistance of Hepatocellular Carcinoma by Modulating IGF1 Using miR-15a-5p. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-8. | 0.8 | 3 |
| 989 | Multi-omics characteristics and immunotherapeutic potential of EZH2 in pan-cancer. Bioscience Reports, 0, , . | 1.1 | 2 |
| 990 | The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. Cancers, 2022, 14, 6151. | 1.7 | 3 |
| 991 | Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma. Molecular Therapy, 2023, 31, 1756-1774. | 3.7 | 3 |
| 992 | Distinct binding pattern of EZH2 and JARID2 on RNAs and DNAs in hepatocellular carcinoma development. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 993 | Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma. Molecular Therapy - Oncolytics, 2023, 28, 88-103. | 2.0 | 6 |
| 994 | Identification of oncogenes and tumor-suppressor genes with hepatocellular carcinoma: A comprehensive analysis based on TCGA and GEO datasets. Frontiers in Genetics, 0, 13, . | 1.1 | 1 |
| 995 | Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211480. | 1.4 | 10 |
| 996 | Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers, 2023, 15, 533. | 1.7 | 25 |
| 997 | Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, . | 3.3 | 30 |
| 998 | Clinical activity of regorafenib in elderly patients with recurrent glioblastoma. Molecular and Clinical Oncology, 2023, 18, . | 0.4 | 1 |
| 999 | A novel antimicrobial peptide <scp>M1</scp>â€8 targets the lysosomal pathway to inhibit autolysosome formation and promote apoptosis in liver cancer cells. Journal of Cellular and Molecular Medicine, 2023, 27, 340-352. | 1.6 | 5 |
| 1000 | Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening. Frontiers in Oncology, 0, 12, . | 1.3 | 3 |
| 1001 | Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Current Oncology, 2023, 30, 1243-1254. | 0.9 | 7 |
| 1002 | Engineering orthotopic tumor spheroids with organ-specific vasculatures for local chemoembolization evaluation. Biomaterials Science, 2023, 11, 2115-2128. | 2.6 | 2 |
| 1004 | Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. European Journal of Internal Medicine, 2023, 111, 37-46. | 1.0 | 3 |
| 1005 | Genes Modulating Butyrate Metabolism for Assessing Clinical Prognosis and Responses to Systematic Therapies in Hepatocellular Carcinoma. Biomolecules, 2023, 13, 52. | 1.8 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1006 | Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study. Journal of Gastrointestinal Oncology, 2022, 13, 3183-3192. | 0.6 | 2 |
| 1007 | Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer. Oxidative Medicine and Cellular Longevity, 2023, 2023, 1-14. | 1.9 | 1 |
| 1008 | Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma. Cancers, 2023, 15, 654. | 1.7 | 7 |
| 1009 | A High-Throughput Sequencing Data-Based Classifier Reveals the Metabolic Heterogeneity of Hepatocellular Carcinoma. Cancers, 2023, 15, 592. | 1.7 | 2 |
| 1010 | The phospholipid flippase <scp>ATP9A</scp> enhances macropinocytosis to promote nutrient starvation tolerance in hepatocellular carcinoma. Journal of Pathology, 2023, 260, 17-31. | 2.1 | 3 |
| 1011 | A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma. Annals of Translational Medicine, 2023, 11, 109-109. | 0.7 | 0 |
| 1013 | The Effect of the Histone Chaperones HSPA8 and DEK on Tumor Immunity in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 2653. | 1.8 | 3 |
| 1014 | Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma. Scientific Reports, 2023, 13, . | 1.6 | 2 |
| 1015 | Analysis of the potential association between ferroptosis and immune in hepatocellular carcinoma and their relationship with prognosis. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 1016 | Radiation therapy in the era of immune treatment for hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 2.2 | 5 |
| 1017 | Drug Resistance in Hepatocellular Carcinoma. , 2023, , 325-348. | | 0 |
| 1018 | Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2023, 15, 719. | 1.7 | 2 |
| 1019 | Upregulated SSB Is Involved in Hepatocellular Carcinoma Progression and Metastasis through the Epithelial-Mesenchymal Transition, Antiapoptosis, and Altered ROS Level Pathway. Oxidative Medicine and Cellular Longevity, 2023, 2023, 1-16. | 1.9 | 0 |
| 1020 | Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis. World Journal of Gastrointestinal Surgery, 0, 15, 273-286. | 0.8 | 0 |
| 1022 | Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy. Acta Biomaterialia, 2023, 162, 98-109. | 4.1 | 5 |
| 1023 | Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 2.2 | 0 |
| 1024 | Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma. International Journal of Pharmaceutics, 2023, 636, 122791. | 2.6 | 5 |
| 1025 | KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway. Experimental Cell Research, 2023, 426, 113564. | 1.2 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1026 | Mechano-modulation of T cells for cancer immunotherapy. Biomaterials, 2023, 297, 122101. | 5.7 | 5 |
| 1027 | Biological functions and therapeutic potential of SHCBP1 in human cancer. Biomedicine and Pharmacotherapy, 2023, 160, 114362. | 2.5 | 4 |
| 1030 | Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-Î³/NSDHL/SREBP1/TGF-Î²1 axis in hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2023, 159, 114254. | 2.5 | 4 |
| 1031 | Efficacy of radiofrequency ablation following transarterial chemoembolisation combined with sorafenib for intermediate stage recurrent hepatocellular carcinoma: a retrospective, multicentre, cohort study. EClinicalMedicine, 2023, 56, 101816. | 3.2 | 2 |
| 1032 | Prognosis and personalized medicine prediction by integrated whole exome and transcriptome sequencing of hepatocellular carcinoma. Frontiers in Genetics, 0, 14, . | 1.1 | 0 |
| 1033 | Gadoxetic acidâ€“enhanced MRI with a focus on LI-RADS v2018 imaging features predicts the prognosis after radiofrequency ablation in small hepatocellular carcinoma. Frontiers in Oncology, 0, 13, . | 1.3 | 0 |
| 1034 | The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 2805. | 1.8 | 6 |
| 1035 | Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art. Journal of Nanobiotechnology, 2023, 21, . | 4.2 | 3 |
| 1036 | Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma. Frontiers in Immunology, 0, 14, . | 2.2 | 0 |
| 1037 | Hsa-miR-22-3p inhibits liver cancer cell EMT and cell migration/ invasion by indirectly regulating SPRY2. PLoS ONE, 2023, 18, e0281536. | 1.1 | 3 |
| 1038 | Microfluidicsâ€enabled Serial Assembly of Lipidâ€siRNAâ€sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. Advanced Materials, 2023, 35, . | 11.1 | 6 |
| 1039 | Metabolomic biomarkers for the diagnosis and post-transplant outcomes of AFP negative hepatocellular carcinoma. Frontiers in Oncology, 0, 13, . | 1.3 | 4 |
| 1040 | Ultrasensitive quantification of trace amines based on N-phosphorylation labeling chip 2D LC-QQQ/MS. Journal of Pharmaceutical Analysis, 2023, 13, 315-322. | 2.4 | 4 |
| 1041 | Discovery of canine drug toceranib phosphate as a repurposed agent against human hepatocellular carcinoma. Liver International, 2023, 43, 928-944. | 1.9 | 0 |
| 1042 | Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, . | 1.6 | 7 |
| 1043 | Metabolism-related signatures is correlated with poor prognosis and immune infiltration in hepatocellular carcinoma via multi-omics analysis and basic experiments. Frontiers in Oncology, 0, 13, . | 1.3 | 3 |
| 1044 | Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study. Clinical Cancer Research, 2023, 29, 1730-1740. | 3.2 | 6 |
| 1045 | <scp>TUBB4B</scp> is a novel therapeutic target in nonâ€alcoholic fatty liver diseaseâ€associated hepatocellular carcinoma. Journal of Pathology, 2023, 260, 71-83. | 2.1 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1046 | Potential oncotherapeutic effects of nutraceuticals against hepatocellular carcinoma: recent advancements. Current Functional Foods, 2023, 01, . | 0.0 | 0 |
| 1047 | A 3D Tumorâ€Mimicking In Vitro Drug Release Model of Locoregional Chemoembolization Using Deep Learningâ€Based Quantitative Analyses. Advanced Science, 2023, 10, . | 5.6 | 2 |
| 1048 | Emerging role of interaction between m6A and main ncRNAs in gastrointestinal (GI) cancers. Frontiers in Immunology, 0, 14, . | 2.2 | 0 |
| 1049 | Atezolizumabe mais Bevacizumabe como Ponte para Transplante HepÃ¡tico no Carcinoma Hepatocelular. Brazilian Journal of Transplantation, 2023, 26, . | 0.1 | 0 |
| 1050 | Atezolizumab plus Bevacizumab as a Bridge for Liver Transplant in Hepatocellular Carcinoma. Brazilian Journal of Transplantation, 2023, 26, . | 0.1 | 0 |
| 1051 | Identification of G protein subunit alpha i2 as a promising therapeutic target of hepatocellular carcinoma. Cell Death and Disease, 2023, 14, . | 2.7 | 1 |
| 1052 | Integrated analysis of RNA-seq in hepatocellular carcinoma reveals competing endogenous RNA network composed of circRNA, lncRNA, and mRNA. Medicine (United States), 2023, 102, e32915. | 0.4 | 1 |
| 1053 | Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Is a Promising Signature to Predict Prognosis and Therapies for Hepatocellular Carcinoma (HCC). Journal of Clinical Medicine, 2023, 12, 1830. | 1.0 | 0 |
| 1054 | MVI-TR: A Transformer-Based Deep Learning Model with Contrast-Enhanced CT for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma. Cancers, 2023, 15, 1538. | 1.7 | 6 |
| 1055 | Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. Clinical and Translational Medicine, 2023, 13, . | 1.7 | 2 |
| 1056 | The correlation between hepatocellular carcinoma susceptibility and XRCC1 polymorphisms Arg194Trp, Arg280His, and Arg399Gln â€“ A meta-analysis. , 2023, 36, 201165. | | 0 |
| 1057 | An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. International Journal of Molecular Sciences, 2023, 24, 5002. | 1.8 | 6 |
| 1058 | Telephone followâ€up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib. Journal of Gastroenterology and Hepatology (Australia), 2023, 38, 1140-1147. | 1.4 | 1 |
| 1059 | Gene variation profile and its potential correlation with clinical characteristics in HBV-associated HCC patients of Sichuan Han nationality in China. Asian Journal of Surgery, 2023, 46, 4371-4377. | 0.2 | 1 |
| 1060 | Phosphatase regenerating liver 3 participates in Integrinβ1/FAK-Src/MAPK signaling pathway and contributes to the regulation of malignant behaviors in hepatocellular carcinoma cells. Journal of Gastrointestinal Oncology, 2023, 14, 863-873. | 0.6 | 2 |
| 1061 | MYC determines lineage commitment in KRAS-driven primary liver cancer development. Journal of Hepatology, 2023, 79, 141-149. | 1.8 | 5 |
| 1062 | Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. Cancers, 2023, 15, 1680. | 1.7 | 8 |
| 1063 | Immunotherapy for HCC: limitations in patients with NASH. Annals of Hepatology, 2023, 28, 100886. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1064 | Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 487-503. | 8.2 | 55 |
| 1065 | Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 2.2 | 20 |
| 1066 | Immunotherapies for advanced hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, . | 1.6 | 4 |
| 1067 | Establishment and validation of a cuproptosis-related lncRNA signature that predicts prognosis and potential targeted therapy in hepatocellular carcinoma. Biotechnology and Genetic Engineering Reviews, 0, , 1-26. | 2.4 | 2 |
| 1068 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. Biomedicines, 2023, 11, 1020. | 1.4 | 6 |
| 1069 | JAK/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: therapeutic implications. Clinical and Experimental Medicine, 2023, 23, 3147-3157. | 1.9 | 4 |
| 1070 | Machine learning integrations develop an antigen-presenting-cells and T-Cells-Infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma. BMC Cancer, 2023, 23, . | 1.1 | 0 |
| 1071 | ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. Journal of Hepatology, 2023, 79, 362-377. | 1.8 | 34 |
| 1072 | Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma. Epigenetics, 2023, 18, . | 1.3 | 12 |
| 1073 | Identification of TIAM1 as a Potential Synthetic-Lethal-like Gene in a Defined Subset of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 6387. | 1.8 | 1 |
| 1074 | Case Report: Solitary metastasis to the appendix after curative treatment of HCC. Frontiers in Surgery, 0, 10, . | 0.6 | 0 |
| 1075 | Nanomedicine-lipiodol formulations for transcatheter arterial chemoembolization. , 2023, , 51-72. | | 0 |
| 1076 | Identification and Experimental Validation of the Prognostic Significance and Immunological Correlation of Glycosylation-Related Signature and ST6GALNAC4 in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 10, 531-551. | 1.8 | 1 |
| 1077 | A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma. Cancer Biomarkers, 2023, 37, 13-26. | 0.8 | 2 |
| 1078 | Ferroptosis in hepatocellular carcinoma: from bench to bedside. Hepatology, 0, Publish Ahead of Print, . | 3.6 | 14 |
| 1079 | The First-in-Human Whole-Body Dynamic Pharmacokinetics Study of Aptamer. Research, 2023, 6, . | 2.8 | 8 |
| 1080 | LncRNA RP11-620J15.3 promotes HCC cell proliferation and metastasis by targeting miR-326/GPI to enhance glycolysis. Biology Direct, 2023, 18, . | 1.9 | 2 |
| 1081 | Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma. Hepatology International, 2023, 17, 753-764. | 1.9 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1083 | DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis. Cellular Oncology (Dordrecht), 2023, 46, 1235-1252. | 2.1 | 3 |
| 1084 | Cellular senescence-related gene signature as a valuable predictor of prognosis in hepatocellular carcinoma. Aging, 0, , . | 1.4 | 1 |
| 1085 | Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy. Biomedicines, 2023, 11, 1166. | 1.4 | 6 |
| 1086 | Western diet unmasks transient low-level vinyl chloride-induced tumorigenesis; potential role of the (epi-)transcriptome. Toxicology and Applied Pharmacology, 2023, 468, 116514. | 1.3 | 3 |
| 1087 | Role of Î²-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma. Cancers, 2023, 15, 2311. | 1.7 | 6 |
| 1088 | Bulk and single-cell transcriptome profiling reveal extracellular matrix mechanical regulation of lipid metabolism reprograming through YAP/TEAD4/ACADL axis in hepatocellular carcinoma. International Journal of Biological Sciences, 2023, 19, 2114-2131. | 2.6 | 8 |
| 1089 | Neutrophil extracellular traps-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in hepatocellular carcinoma. Journal of Radiation Research and Applied Sciences, 2023, 16, 100577. | 0.7 | 1 |
| 1117 | Cancers digestifs. , 2023, , 199-205. | | 0 |
| 1156 | Pathology of Digestive System Malignancies. , 2023, , 259-273. | | 0 |
| 1194 | Hepatobiliary-phase gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid MRI for pretreatment prediction of efficacy-to-standard-therapies based on Barcelona Clinic Liver Cancer algorithm: an up-to-date review. European Radiology, 2023, 33, 8764-8775. | 2.3 | 0 |
| 1252 | Application of the Human Amniotic Membrane as an Adjuvant Therapy for the Treatment of Hepatocellular Carcinoma. Advances in Experimental Medicine and Biology, 2023, , . | 0.8 | 0 |
| 1258 | Liver transplantation: the recipient. , 2024, , 997-1283. | | 0 |
| 1284 | Emerging role of RNA modification and long noncoding RNA interaction in cancer. Cancer Gene Therapy, 0, , . | 2.2 | 0 |